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As the Canadian population ages, the burden on our community and health care 
systems of age-related conditions, such as dementia, is increasing and research in these areas 
is becoming more critical. Dementia is a major health concern for adults as they age. 
Although dementia is the most common neurological disease in older adults, headaches are 
the most common neurological disorder across all ages. Migraines are a common form of 
headache disorders that affect millions of people worldwide. Both neurological disorders—
dementia and migraines—cause significant impairment for the individual and strain on their 
caregivers, as well as substantial economic impact on society. The relationship between 
migraines and late-life cognitive health outcomes has not yet been thoroughly explored. 
 Using data from the Manitoba Study of Health and Aging (MSHA), the relationship 
between migraines and various late-life cognitive health outcomes, including overall 
dementia, Alzheimer’s disease (AD), vascular dementia (VaD) and cognitive impairment-no 
dementia (CIND), was examined. As migraines and cognitive impairments are often 
associated with various comorbid disorders, analyses also investigated the impact of possible 
associated intervening variables: hypertension, diabetes, stroke, myocardial infarction and 
other heart conditions. A secondary focus of this project was to examine whether the 
association between migraines and late-life cognitive health outcomes varied by sex and 
family history of dementia. 
Migraines were a significant risk factor for both overall dementia and AD. However, 
the relationship between migraines and overall dementia appeared to be driven by the 
significant relationship between migraines and AD. Having a history of migraines was not 





variable in the relationship between migraines and VaD, indicating that the vascular event, 
stroke, plays an important part in the migraine-VaD relationship. A history of migraines was 
not a significant risk factor for CIND.  
Results could not be stratified by sex because of all participants with migraines, no 
men developed dementia and only one man developed CIND. Furthermore, despite a lack of 
significant results from models stratified by family history of dementia, the results are 
suggestive of possible genetic influences in the relationship between migraines and AD.  
Overall, this study supports the conclusion that migraines are a significant risk factor 
for late-life cognitive health, specifically AD. In addition, this study highlights the possibility 
that vascular events, such as stroke, may play an important role in the relationship between 
migraines and VaD. Increased understanding of mid-life risk factors for late-life cognitive 
health outcomes has important implications for researchers and clinicians in the form of 
interventions, preventative treatments and medications. In addition, this study suggests that 
there is a need for further research regarding possible genetic influences in the relationship 
between migraines and AD. As it was unable to be fully addressed in this study, future 
studies should investigate gender differences among individuals with migraines developing 
late-life cognitive health outcomes. This research aims to help develop new strategies that 
could aid in the prevention of cognitive decline, improve quality of life, and increase the 
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 As the Canadian population ages, the burden on our community and health care 
systems of age-related conditions, such as dementia, is increasing. According to a recent 
report by the Alzheimer Society, “Rising Tide: The Impact of Dementia on Canadian 
Society” (2010), approximately 500,000 people in Canada are currently suffering from 
dementia. The prevalence of dementia is expected to increase to approximately 1.1 million 
people by the year 2038 (Alzheimer Society, 2010). Trends such as this are causing increased 
awareness of the importance of research in this area.  
 Specifically, research regarding mid-life risk factors and their relationship with 
possible late-life cognitive health outcomes is becoming more of a focus. Various mid-life 
risk factors, such as smoking; lower levels of education; diabetes; and cardiovascular disease, 
including stroke, have been found to be related to the development of late life cognitive 
health outcomes (see reviews by Blennow, de Leon & Zetterberg, 2006; Kester & Scheltens, 
2009; Patterson et al., 2007). It has become vital to determine how these mid-life risk factors 
can be treated or prevented to improve quality of life and increase the likelihood of healthy 
aging. 
Although dementia is the most common neurological disease in older adults, 
headaches are the most common neurological disorder across all ages. Headache disorders 
are a serious neurological phenomenon that affect almost half of the global population of 
adults (Stovner et al., 2007). Migraines are the most debilitating form of headaches and 
affect 11% of the population: 20% of women and 8% of men (Diener & Beck, 2009; 





cognitive impairment has not been thoroughly examined. However, Tyas et al. (2001) found 
migraines to be a significant risk factor for Alzheimer’s disease (AD). 
The primary purpose of this thesis study is to determine if migraines are a risk factor 
for late-life cognitive health outcomes (overall dementia, AD, vascular dementia (VaD) and 
cognitive impairment-no dementia (CIND)). Analyses are based on data from the Manitoba 
Study of Health and Aging (MSHA), a longitudinal population-based cohort study, and 
extend the earlier work conducted by Tyas et al. (2001) using these data. Analyses also 
investigated the impact of possible intervening variables: hypertension, diabetes, stroke, and 
myocardial infarction. A secondary focus of this project was to examine whether the 
association between migraine and late-life cognitive health outcomes varied by sex or family 
history of dementia. 
Identifying risk factors for cognitive health outcomes in late life is an important 
research area, given the current and expected increases in the proportion of older adults in the 
population. Identifying a mid-life risk factor for cognitive outcomes in latelife will allow 
earlier recognition of at-risk individuals. In addition, it will provide a rationale for the 
development of new preventative strategies and treatments targeting migraines and 
associated intervening variables. It is critical to continue to develop new strategies that will 






2. Literature Review 
 
2.1. Late-Life Cognitive Health Outcomes 
2.1.1. Definition 
2.1.1.1. Dementia 
Dementia is a neurological syndrome that is characterized by a decline in cognitive 
function, of which a common symptom is memory loss. Various areas of the brain can be 
affected depending on the type and stage of dementia. As a result, cognitive symptoms can 
range from language dysfunction to visual perception issues and executive function problems 
(see review by Kester & Scheltens, 2009).The intensity of dementia symptoms can range 
from mild to severe and can be linked to the stages of dementia progression (see review by 
Burns & Iliffe, 2009).  
The two most common types of dementia are AD and VaD, accounting respectively 
for 54% and 16% of all late-onset cases of dementia (see review by Kester & Scheltens, 
2009). Two common causes of dementia that account for a large portion of the remaining 
30% of cases are frontotemporal dementia and dementia with Lewy bodies (see reviews by 
Kester & Scheltens, 2009; Tedeschi et al., 2008). Mixed dementia, combining characteristics 
of both AD and VaD, also contributes to the number of dementia cases (see reviews by 
Kester & Scheltens, 2009; Tedeschi et al., 2008). Other subtypes of dementia include those 
resulting from alcoholism, depression, Huntington’s disease, and Parkinson’s disease (see 
review by Kester & Scheltens, 2009). 
The early stages of dementia are often misinterpreted as being a part of normal aging 
(see review by Tyas & Gutmanis, 2008). This is because with aging there is a normal level of 





review by Peters, 2006). Between 25% and 75% of older adults report that their memory is 
worse than when they were younger (Chertkow et al., 2008). Occasional forgetfulness or 
normal memory function decline is not a form of dementia, as dementia involves impairment 
that is severe enough to cause difficulty with daily functioning. 
 
2.1.1.2. Alzheimer’s Disease 
AD is an irreversible, progressive, neurodegenerative disease affecting older adults. 
Symptoms of AD have been categorized into three primary groups: cognitive dysfunction, 
psychiatric symptoms, and difficulty performing daily activities (see review by Burns & 
Iliffe, 2009). Cognitive dysfunction symptoms include memory loss, language problems and 
issues with executive function. For instance, problems with higher-level learning or 
intellectual coordination skills are common. Psychiatric symptoms include emotional and 
behavioural disturbances, such as depression, agitation, delusions or hallucinations (see 
review by Burns & Iliffe, 2009). Difficulties performing daily activities, such as driving, 
shopping, dressing or eating, are often noticed by family or friends of the individual with AD 
(see reviews by Burns & Iliffe, 2009; Cummings, 2004; Tedeschi et al., 2008). Such day-to-
day activities are often described as either instrumental activities (e.g., driving or managing 
money) or basic activities (e.g., dressing or eating).  
 
2.1.1.3. Vascular Dementia 
Vascular cognitive impairment or vascular cognitive disorder are broad terms that are 
used to encompass a wide variety of vascular-based dementias or disorders, such as post-





arteriopathy with subcortical infarcts and leukencephalopathy) and VaD (see review by 
Jellinger, 2008). VaD is a form of dementia characterized by cognitive dysfunction due to 
vascular damage in the brain (see review by Kester & Scheltens, 2009). VaD has 
traditionally been associated with cardiovascular disease and associated risk factors, such as 
hypertension or hyperlipidemia (see reviews by Erkinjuntti & Gauthier, 2009; Viswanathan, 
Rocca & Tzourio, 2009). Severity of VaD is determined by the burden of vascular damage in 
the brain: individuals with more vascular lesions or infarcts in the brain will suffer from 
more severe dementia symptoms (see review by Jellinger, 2008). The overlap between AD 
and VaD is becoming more obvious as vascular risk factors, such as hypertension, diabetes 
or hypercholesterolemia, are more commonly diagnosed in patients with AD. Also, autopsy 
studies have noted the presence of vascular lesions coexisting with classic AD pathology (del 
Ser et al., 2005; Snowdon et al., 1997). The term “mixed dementia” has been used to refer to 
an overlap or combination of AD and vascular diseases of the brain, including 
cerebrovascular disease and vascular encephalopathy (see reviews by Jellinger & Attems, 
2007; Kalaria, 2002). However, not all dementia definitions recognize mixed dementia as a 
separate form of dementia (see review by Jellinger & Attems, 2007). 
 
2.1.1.4. Mild Cognitive Impairments 
There are many terms used to describe forms of cognitive disorders milder than 
dementia. Some of these terms include CIND, mild cognitive impairment (MCI), mild 
dysfunction, pre-dementia, pre-Alzheimer’s disease or borderline dementia (Tuokko & 
Frerichs, 2000). CIND and MCI have been the most popular terms and the most consistently 





memory loss that is not accompanied by any noticeable decline in day-to-day functioning or 
other non-memory cognitive dysfunction. These symptoms are not severe enough to meet 
criteria for a diagnosis of any type of dementia or other neurological explanation of the 
memory complaint. This is an important aspect of CIND or MCI (Chertkow et al., 2007; see 
reviews by Petersen et al., 2001; 2009). CIND and MCI are categorized based on their 
etiology. CIND can be divided into multiple subcategories: amnestic, vascular, 
medical/toxic, metabolic, psychiatric, neurologic, mixed, and not specified (Chertkow et al., 
2007). MCI is typically divided into either amnestic, non-amnestic or multiple domain types 
(Nagai, Hoshide & Kario, 2010; Petersen et al., 2001). Many studies suggest that MCI or 
CIND is a precursor of AD (Tyas et al., 2007; see reviews by Burns & Iliffe, 2009; Tedeschi 
et al., 2008). 
 
2.1.1.5. Diagnostic Criteria 
Because of the variety of types or causes of dementia, there is also a wide range of 
diagnostic criteria used. Screening tools are used to distinguish between normal levels of 
cognitive decline related to aging and cognitive impairment due to disease or disorder. 
Screening tools are quick and inexpensive to administer and are most often used to identify 
individuals to target for a full neurological assessment, which is both lengthy and expensive. 
Common screening tools for cognitive impairment include the Mini-Mental State Exam 
(MMSE), the Modified Mini-Mental State Exam (3MS), as well as the Montreal Cognitive 
Assessment (MoCA) (Chertkow et al., 2007; Nasreddine et al., 2005). 
Dementia is most commonly diagnosed clinically using the DSM-IV. Once this 





criteria to determine the type of dementia. Both neuropsychological and pathologic 
diagnostic criteria have been developed to aid in the diagnosis of AD. There are three 
primary neuropsychological criteria that are currently utilized when making clinical 
diagnoses of AD: National Institute of Neurologic and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders (NINCDS-ADRDA) (McKhann et al., 1984), 
DSM-IV (DSM-IV, 1994) and Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) (Morris et al., 1989) criteria. The clinical definition most widely used in research 
is the NINCDS-ADRDA (McKhann et al., 1984; see reviews by Cummings, 2004; 
Cummings et al., 1998; Tedeschi et al., 2008). The NINCDS-ADRDA definition allows for 
classification of AD as definite, probable or possible (McKhann et al., 1984; see reviews by 
Cummings et al., 1998; Tedeschi et al., 2008). However, a clinical diagnosis of “definite 
AD” remains presumptive until confirmed by a post-mortem neuropathologic examination. 
Various pathologic criteria have been developed to help diagnose AD. AD pathology 
is most definitively determined post-mortem, although new imaging techniques have begun 
to allow clinicians to identify plaques within the brain antemortem. The CERAD (Mirra et 
al., 1991) and the National Institute for Aging - Ronald and Nancy Reagan Institute of 
Alzheimer’s Disease (NIA-RI) (NIA-Reagan, 1997) criteria are commonly used pathologic 
diagnostic criteria. The CERAD neuropathologic criterion uses the number of plaques to 
determine a neuropathologic diagnosis of no AD, possible AD, probable AD or definite AD 
(Mirra et al., 1991). The NIA-RI criteria combine the CERAD criteria with Braak staging 
(NIA-Reagan, 1997) and categorize the likelihood that dementia is due to AD as low, 
intermediate or high (NIA-Reagan, 1997). Braak staging is a quantification of the number 





& Braak, 1991). Severity of AD neuropathology is most often assessed using Braak staging 
(Braak & Braak, 1991). (See Section 2.1.4.2 for a discussion of neurofibrillary tangles and 
other AD pathologies.) 
VaD can be diagnosed using a variety of criteria including the DSM-IV (DSM-IV, 
1994) and the National Institute of Neurological Disorders and Stroke - Association 
Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) 
(Roman et al., 1993) criteria. The NINDS-AIREN definition includes possible VaD, 
probable VaD and definite VaD (Roman et al., 1993). The criteria for probable VaD 
specifies that the individual must be suffering from cognitive decline that can be directly 
related to cerebrovascular disease, whereas the criteria for definite VaD also specifies that 
cerebrovascular disease must be confirmed by biopsy or autopsy and that AD 
neuropathology must not be present (Roman et al., 1993). A diagnosis of possible VaD is 
most often applied when some key features of the above definitions are missing (Roman et 
al., 1993). Clinical diagnoses are made using the DSM-IV and NINDS-AIREN, whereas 
neuropathologic diagnoses are generally based on brain imaging, which can be used to assess 
the level of vascular lesion burden on the brain (see review by Kester & Scheltens, 2009). 
The Hachinski Ischemic Score is used to determine the level of vascular burden on the brain; 
a higher score indicates that an individual is more likely to have vascular dementia due to the 
severity of vascular lesions (Hachinski et al., 1975). 
There are no gold standard diagnostic criteria for mild cognitive impairment. A lower 
score on the Global Deterioration Scale (GDS) or Clinical Dementia Rating scale (CDR) or a 
normal range score on the MMSE or 3MS may indicate CIND/MCI (Chertkow et al., 2008; 





classification as stage 2 or 3 on the GDS will most often indicate MCI or CIND (Berg, 1988; 
Morris, 1993; Petersen et al., 1999; Reisberg et al, 1982; see review by Petersen et al., 2009). 
The MoCA is a cognitive screening tool that has high specificity and sensitivity for detecting 
MCI in individuals who have a normal score on the MMSE (Nasreddine et al., 2005). Often 
clinicians use a variety of cognitive tests, scales, or criteria in order to make a more complete 
diagnosis. Imaging can be used to assess MCI neuropathology before death (Solé-Padullés et 
al., 2007). In particular, the possible locations of lesions in the brains and overall brain 
atrophy as well as hippocampal atrophy can be identified through the use of brain imaging 
(Solé-Padullés et al., 2007; see review by Petersen et al., 2009). 
 
2.1.2. Rates and Impact on the Population 
2.1.2.1. Incidence and Prevalence of Dementia 
Since dementia is a neurological syndrome that primarily affects older adults, the 
incidence of dementia is increasing globally as the population of older adults increases 
(Alzheimer Society, 2010; Alzheimer’s Disease International, 2009; The Canadian Study of 
Health and Aging Working Group, 2000). According to a recent report by the Alzheimer 
Society, “Rising Tide: The Impact of Dementia on Canadian Society” (2010), the projected 
incidence of dementia in Canada will increase 2.5 times from 2008 to 2038. The prevalence 
of dementia across all ages in Canada is expected to more than double in 30 years: from 
approximately 500,000 people (1.5% of the population) in 2008 to 1.1 million people (2.8% 
of the population) by 2038 (Alzheimer Society, 2010). The World Alzheimer’s Report 





in 2010. The worldwide prevalence of dementia is estimated to double every 20 years, to 
65.7 million in 2030 and 115.4 million in 2050. 
Age and gender differences have been observed in rates of dementia. In Canada, the 
prevalence of overall dementia has been shown to be higher in females than in males 
(Alzheimer Society, 2010). In the US, 14% of people over the age of 70 have dementia; 16% 
of those are women and 11% are men (Plassman et al., 2007; Alzheimer’s Association, 
2009). However, some studies have shown that age-specific incidence rates show no 
significant gender differences (Alzheimer’s Association, 2009; Andersen et al., 1999; 
Fitzpatrick et al., 2004; Ruitenberg et al., 2001). Despite these inconsistent results in gender 
differences in the incidence vs. prevalence of dementia, the prevalence of dementia would be 
expected to be higher in women than in men because of women’s greater life expectancy and 
the strong association between age and dementia (Alzheimer’s Association, 2009; 
Ruitenberg et al., 2001; see review by Patterson et al., 2007). Prevalence of dementia in the 
population also increases by age groups: from 1% of individuals 60-65 years of age, to 10-
35% of those over 85 years (see reviews by Kester & Scheltens, 2009; Prince, 2004; 
Tedeschi et al., 2008). 
 
2.1.2.2. Incidence and Prevalence of Alzheimer’s Disease 
Alzheimer’s disease is the most common form of dementia (see reviews by Kester & 
Scheltens, 2009; Tedeschi et al., 2008). More than 24 million people worldwide have AD; 
within Canada, approximately 300,000 people have AD (Alzheimer Society, 2010). 
Approximately 1% of older adults between the ages of 60 and 64 suffer from AD, increasing 





between 80 and 85 and 40% of adults over 85 years (Cummings et al., 1998). These numbers 
are expected to rise as the population ages. Studies have shown that women are more likely 
than men to have AD; specifically, prevalence studies generally demonstrate higher risk in 
women than men (Alzheimer’s Association, 2009; see review by Musicco, 2010). Some 
studies have speculated that these differences in rates may be due to the fact that women live 
longer than men (Hebert et al., 2001; Ruitenberg et al., 2001). Some studies have found no 
differences in age-specific incidence rates (Alzheimer’s Association, 2009; Hebert et al., 
2001; Heun & Kockler, 2002; Ruitenberg et al., 2001) although in the oldest old, incidence 
of AD may be higher in women than in men (Andersen et al., 1999; Ruitenberg et al. 2001). 
 
2.1.2.3. Incidence and Prevalence of Vascular Dementia 
Vascular dementia is the second most common form of dementia, accounting for 15-
25% of prevalent dementia cases (see review by Jellinger, 2008). VaD is more common in 
men compared to women, demonstrated by prevalence rates among those under the age of 79 
ranging from 2.2% in women to 16.3% in men (see reviews by Leys, Pasquier & Parentti, 
1998). Ruitenberg et al. (2001) found that across all age groups, men were at a higher risk of 
developing VaD than were women. It has been speculated that this gender difference in VaD 
rates may be due to the protective effects of estrogens in women or the association between 
male gender and cardiovascular disease (Andersen et al., 1999). Mixed dementia, or overlap 
between AD and VaD, accounts for approximately 5-10% of all cases of dementia (see 
review by Jellinger & Attems, 2007). However, due to issues with under-diagnosis or 







2.1.2.4. Incidence and Prevalence of Mild Cognitive Impairments 
It is difficult to determine the prevalence or incidence of MCI or CIND, as it may go 
undetected and therefore undiagnosed until it progresses to dementia. However, the 
prevalence of MCI has been estimated to be two to three times higher than that of AD and 
affect approximately 15% of the non-demented population (see reviews by Petersen et al., 
2009; Tedeschi et al., 2008). It has been estimated that approximately 40-60% of people with 
MCI will eventually progress to meet criteria for AD; this varies by MCI subtype (see review 
by Tedeschi et al., 2008). 
 
2.1.2.5. Impact of Cognitive Impairment 
Dementia is a severe, debilitating disease that affects almost one-third of the older 
adult population, causing significant global economic impact. According to a recent report by 
the Alzheimer Society, “Rising Tide: The Impact of Dementia on Canadian Society” (2010), 
the economic burden of dementia as of 2008 is $10 billion annually; this is expected to rise 
to $97 billion by the year 2038. These estimates do not include unpaid services provided by 
caregivers, which have been estimated to be valued at $5 billion in 2008, increasing to $56 
billion by the year 2038 (Alzheimer Society, 2010). Medical care costs for an AD patient are 
a significant concern, in addition to any loss of income due to absenteeism of either the AD 
patient or the caregiver. 
Caregiver burden is becoming a growing concern, as families of dementia patients 
contend with the financial and emotional stresses associated with dementia. The emotional 





psychologically exhausting, for both the individual with dementia as well as the caregiver 
(Black et al., 2009; see review by Burns & Iliffe, 2009). Often the level of disability 
necessitates acquiring additional medical help, such as home nurses or in the most severe 
cases, institutionalization (Rockwood, Stolee & McDowell, 1996). 
According to the World Health Report (2001), AD and other dementias are ranked 
13th as a cause of disability for all ages in both sexes and 9th for women alone. The Global 
Burden of Disease Report (World Alzheimer Report, 2009) estimates that dementia accounts 
for 4.1% of total disease burden (Disability-Adjusted Life Years) among people 60 years and 
older, 11.3% of years lived with disability and 0.9% of years of life lost. Dementia does not 
affect memory alone; it also has psychological and physical symptoms, which combine to 
cause disability. Psychological symptoms of dementia range from depression to behavioural 
changes to hallucinations (see review by Burns & Iliffe, 2009). Since motor function is 
affected by various forms of dementia, physical disability often occurs, such as balance 
problems resulting in falls (see review by Burns & Iliffe, 2009).  
Estimated survival time from onset of dementia or dementia diagnosis ranges from 3-
10 years (Wolfson et al., 2001; Xie et al., 2008; see review by Zanetti, Solerte & Cantoni, 
2009). Dementia itself does not directly cause death, but the neurological systems that are 
affected can increase the risk of death. For example, problems with swallowing food are 
common in those suffering from AD, which can lead to food particles being inhaled into the 
lungs, possibly causing pneumonia and subsequent death (Ganguli et al., 2005). AD is 
currently the 6th leading cause of death in the US and the 8th leading cause of death in Canada 
in both sexes (Alzheimer’s Association, 2009; Statistics Canada, 2010). In those over the age 





In Canada, for those between the age of 75 and 84 years, AD is the 6th leading cause of 
death; in those over the age of 85, AD is the 5th leading cause of death (Statistics Canada, 
2010). Deaths related to dementia are most often attributed to AD. However, the mortality 
rate of VaD may be higher than AD, because of the relationship between VaD and heart 
attack or stroke (see review by Leys, Pasquier & Parnetti, 1998). These vascular events are 
often fatal and are significantly associated with VaD (see review by Leys, Pasquier & 
Parnetti, 1998).  
It is difficult to measure the impact of CIND or MCI on society, as many individuals 
are undiagnosed until further impaired. CIND and MCI may progress to dementia, with all its 
associated impacts on the individual, their family and society. However, even if these mild 
cognitive impairments do not become more severe, they may be a cause of concern for the 
affected individual. In addition, new treatments targeted at individuals with these 
impairments add to their economic impact. 
 
2.1.3. Risk and Protective Factors 
2.1.3.1. Overview of Risk and Protective Factors 
A wide range of risk factors have been identified for dementia. The most definitive, 
non-modifiable risk factors for dementia are age, sex and genetics (see reviews by Blennow, 
de Leon & Zetterberg, 2006; Patterson et al., 2007). The most consistent risk factor for all 
forms of dementia is age (see reviews by Kester & Scheltens, 2009; Patterson et al., 2007). 
The risk for many diseases, including dementia, increases as people grow older. Hence, 





other vascular events, becomes more common. Risk factors for dementia can be divided into 
environmental, behavioural, lifestyle and genetic factors, as well as diseases and disorders. 
Risk factors for overall dementia are often difficult to determine, as the various 
factors that will convey the most risk for an individual are driven by the proportion of 
dementia subtypes within the population. For instance, in a population of individuals with 
dementia, if the majority of these individuals suffer from AD, then the risk factors identified 
can likely be attributed to AD. 
 
2.1.3.2. Alzheimer’s Disease 
 The majority of risk factor research has focused on AD, since it is the most common 
cause of dementia in most countries around the world. Sociodemographic risk factors for AD 
include age, female sex and lower educational status (Hebert et al., 2001; Ruitenberg et al., 
2001; Tyas et al., 2001; see review by Patterson et al., 2007). A summary of AD risk factors 






Table 1: Risk factors for dementia’s major subtypes: Alzheimer’s disease and vascular 
dementia 
 
  AD VaD 
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Coronary Heart Disease 













* AD: Alzheimer’s disease; VaD: vascular dementia; APOE (ε4): apolipoprotein E genotype, 






2.1.3.2.1. Behavioural, Lifestyle and Environmental Factors 
Certain lifestyle or behavioural factors have been found to increase the risk of 
developing AD (e.g., smoking, alcohol consumption, decreased physical activity, increased 
body mass index (BMI), and occupation) (Fitzpatrick et al., 2009; Laurin et al., 2001; Tyas et 
al., 2001; see reviews by Beydoun, Beydoun & Wang, 2008; Luchsinger & Mayeux, 2007; 
Patterson et al., 2007). Based on Canadian Study of Health and Aging (CSHA) data, Laurin 
et al. (2001) speculated that physical activity may act as a protective factor since it is related 
to lower BMI or weight and decreased risk for diabetes mellitus, hypertension, stroke and 
various vascular health outcomes. Some researchers have suggested that the association 
between AD and increased BMI may reflect underlying vascular diseases (Laurin et al., 
2001; see review by Patterson et al., 2007). Smoking and alcohol consumption may be 
related to AD as they are often associated with cardiovascular disease and various vascular 
risk factors in an individual (Tyas et al., 2003; see review by Tyas, 2001). 
 
2.1.3.2.2. Genetic Factors 
There are two types of genetic factors: those that determine development of AD and 
those that increase the risk or susceptibility of developing AD (see review by Tyas & 
Gutmanis, 2008). Genetic factors that are considered to be deterministic are the cause of 
familial AD, whereas genetic factors that increase the risk of developing AD are often 
considered one of the causes of sporadic AD (see review by Tyas & Gutmanis, 2008). 
Familial AD is a rare autosomal dominant disorder that is the cause of early-onset AD (see 
reviews by Blennow, de Leon & Zetterberg, 2006; Tyas & Gutmanis, 2008). Familial AD is 





presenilin-2 (see reviews by Burns & Iliffe, 2009; Tyas & Gutmanis, 2008). These mutations 
are found on chromosomes 21, 14 and 1, respectively (see review by Burns & Iliffe, 2009). 
Individuals with APP and presenilin gene mutations will develop AD if they live long 
enough, and therefore these gene mutations are considered deterministic (see review by Tyas 
& Gutmanis, 2008).  
Sporadic or late-onset AD is more common than familial AD and may be caused by 
various genetic or environmental risk factors (see reviews by Tyas & Gutmanis, 2008; 
Blennow, de Leon & Zetterberg, 2006). The apolipoprotein E (APOE-ε4) allele, located on 
chromosome 19, has been found to be associated with increased risk of developing AD and is 
often considered a primary cause of sporadic AD (Azad, Al Bugami & Loy-English, 2007; 
see reviews by Blennow, de Leon & Zetterberg, 2006; Patterson et al., 2007). APOE-ε4 leads 
to accelerated deposition of amyloid in the brain (see review by Cummings, 2004). A 
Swedish twin study estimated that between 60% and 80% of AD cases can be attributed to 
APOE (i.e., where an individual has at least one APOE-ε4 allele) (Gatz et al., 2005a; 
Pedersen et al., 2004). As the number of APOE-ε4 alleles increases, the risk of late-onset AD 
increases from 20% to 90%. The increase in number of APOE-ε4 alleles also affects age of 
onset, decreasing the mean age of onset from 84 to 68 years (see review by Blennow, de 
Leon & Zetterberg, 2006). APOE-ε4 status may have a deleterious effect on hippocampal 
pathology and memory performance that is greater in women than in men (Fleisher et al., 
2005).  
Inflammation plays an important role in dementia neuropathology and 
neurophysiology. Recent studies have found that specific inflammatory genes increase the 





interlukin-1α-889 and interleukin-1β+3953 may indicate an increased risk for AD (Hedley et 
al., 2000; Nicoll et al., 2000; see review by Griffin & Mrak, 2002). Researchers have also 
found that the combination of APOE-ε4 and tumour necrosis factor-α identifies those with an 
increased risk of developing AD (McCusker et al., 2001; see review by McGeer & McGeer, 
2001). 
 
2.1.3.2.3. Health Status and Conditions 
A variety of diseases, disorders and health conditions have been found to be related 
to, comorbid with, or risk factors for AD, including diabetes mellitus, epilepsy, Down’s 
syndrome, hyperhomocysteinemia, hyperthyroidism, depression, sex hormone levels and 
head trauma. Specifically, the association between mid-life vascular risk factors and the 
development of dementia, including AD, in late life has been well documented (Alonso et al., 
2009; Fillit et al., 2008; Hebert et al., 2000; Whitmer et al., 2005). Various vascular risk 
factors for AD have been identified, including hyperlipidemia, hypertension, atherosclerosis, 
stroke and coronary heart disease (Hebert et al., 2000; Tyas et al., 2001; see reviews by 
Duron & Hanon, 2008; Graves, 2004; Patterson et al., 2007; Tyas & Gutmanis, 2008). 
 
2.1.3.2.3.1. Cardiovascular Disease 
A variety of cardiovascular disease (CVD) outcomes and risk factors have been found 
to be related to dementia, including AD and VaD. Hypertension in mid-life has been shown 
to be a risk factor for cognitive decline and dementia (Freitag et al., 2006; Launer et al., 
1995, 2000; Nagai, Hoshide & Kario, 2010; Skoog et al., 1996; Stewart et al., 2009). Studies 
have implicated both high and low systolic and diastolic blood pressure in the development 





association between mid-life high systolic blood pressure and late-life cognitive impairment 
has been observed for both AD and VaD (Freitag et al., 2006; Launer et al., 1995, 2000; 
Stewart et al., 2009). 
In addition to vascular risk factors being associated with AD, vascular events, such as 
coronary artery disease, heart disease, atherosclerosis and heart failure, have also been shown 
to be risk factors for dementia, including AD (Qui, Winblad & Alessandra, 2006; Tyas et al., 
2001; see reviews by Duron & Hanon, 2008; Graves, 2004; Patterson et al., 2007; Tyas & 
Gutmanis, 2008). Cerebrovascular disease, including the occurrences of symptomatic stroke 
or silent stroke, also increases the risk of developing AD (Honig et al., 2003; Ivan et al., 
2004; Schneider et al., 2007; Snowdon et al., 1997; Troncoso et al., 2008; Vermeer et al., 
2003a,b,c). Atherosclerosis has been found to increase the risk of developing dementia, 
including AD (Honig et al., 2005; Roher at al., 2010; see review by Duron & Hanon, 2008). 
However, this relationship may be mediated by CVD outcomes, such as stroke, coronary 
heart disease and congestive heart failure. Coronary heart disease and congestive heart 
failure have been found to be associated with cognitive decline and impairment (see review 
by Duron & Hanon, 2008). 
 
2.1.3.2.3.2. Diabetes 
Diabetics have an increased risk of cognitive dysfunction or dementia. Diabetes 
mellitus has been found to be a significant risk factor for AD (Arvanitakis, 2004; Kopf & 
Frölich, 2009; Luchsinger et al, 2001; Saczynski et al., 2008; see reviews by Launer, 2009; 
Patterson et al., 2007). Using data from the Religious Orders Study, Arvanitakis et al. (2004) 





Confidence Interval (CI):1.10-2.47) of developing AD compared to those without diabetes. 
Diabetes may increase the risk of developing AD as it has been associated with the formation 
of beta-amyloid (Aβ) and inflammatory factors in the brain (see review by Craft, 2007). 
Diabetes mellitus often causes insulin resistance, which has been shown to be related to the 
formation of Aβ and various inflammatory factors in the brain (see review by Craft, 2007). 
This indicates that diabetes is indirectly associated with increased risk of AD (see review by 
Craft, 2007). However, diabetes is also closely associated with many vascular risk factors, 
which may also contribute to the relationship between diabetes and AD. 
 
2.1.3.2.3.3. Depression 
The presence of depressive symptoms has been shown to be related to or predictive of 
the development of dementia (Gatz et al., 2005b; Luchsinger et al., 2008; Ownby et al., 
2006; see review by Patterson et al., 2007). However, results of studies on the relationship 
between AD and depression have sometimes been contradictory. Studies have shown that 20-
30% of people with AD also have depressive symptoms (see review by Tsuno & Homma, 
2009). It has been speculated that depressive symptoms may precede the onset of AD, 
coincide with AD development or possibly follow AD development. Using MSHA data, 
Gatz, et al. (2005b) found that depressive symptoms were predictive of AD and dementia 
development over five years, suggesting that depression is in fact a prodromal symptom of 
AD. These results are in contrast with results from a meta-analysis by Ownby et al. (2006), 
which considered depression more a risk factor than a prodrome for AD. Ownby et al. (2006) 
found that individuals with a history of depression were more likely to be diagnosed with AD 





subsequent diagnosis of AD was related to subsequent development and diagnosis of AD. 
Their results suggest that the interval was significant and positively related to an increased 
risk of developing AD. This finding suggests that depression is a risk factor for AD, rather 
than a prodrome of the disease (Ownby et al., 2006). 
 
2.1.3.2.3.4. Epilepsy 
People suffering from epilepsy have a two to five times increased risk of stroke, 
migraine and AD (Gaitatzis et al., 2004; Hermann et al., 2008; Tellez-Zenteno, Matijevic & 
Wiebe, 2005). The relationship between epilepsy and cognitive impairment may be due to 
the underlying neuropathology of epilepsy (see Section 2.2.3.2.), which either causes or 
exacerbates cognitive dysfunction (see review by Motamedi & Meador, 2003). 
 
2.1.3.3. Vascular Dementia 
 Research has focused less on risk factors for VaD than for AD, resulting in fewer risk 
factors being identified. Sociodemographic risk factors for VaD include age, lower 
educational status, living in rural areas and male sex (Andersen et al., 1999; Ruitenberg et al., 
2001). A summary of VaD risk factors, including behavioural, lifestyle and environmental 
risk factors, is shown in Table 1. 
 
 
2.1.3.3.1. Behavioural, Lifestyle and Environmental Factors 
 Lifestyle or behavioural factors associated with increased risk of developing VaD are 





decreased physical activity and unhealthy diet (Hebert et al., 2000; see reviews by Leys & 
Pasquier, 1998; Patterson et al., 2007).  
 
2.1.3.3.2. Genetic Factors 
 The majority of research pertaining to genetic factors for dementia has focused on 
AD and specifically inherited, familial AD. However, the presence of an APOE-ε4 allele, in 
addition to increasing the risk of developing AD, has also been observed to increase the risk 
of VaD as well as mixed dementia, according to data from the CSHA (Hebert et al., 2000). 
Researchers have speculated that this relationship is due to overlapping pathology of AD and 
VaD (Hebert et al., 2000). However, APOE-ε4 could be linked directly to VaD given 
APOE’s role in brain metabolism and cholesterol transport (Hebert et al., 2000; see reviews 
by Martins et al., 2009; Morley & Banks, 2010) 
 
2.1.3.3.3. Health Status and Conditions 
 A variety of diseases and disorders have been associated with VaD, such as diabetes 
mellitus and depression. Many vascular health conditions have been found to be associated 
with VaD, including hypertension, hyperlipidemia, atherosclerosis, stroke and coronary heart 
disease (Hebert et al., 2000; Lindsay, Hebert & Rockwood, 1997; see reviews by Patterson et 









2.1.3.3.3.1. Cardiovascular Disease 
Although research has begun to demonstrate the relationship between CVD and AD, 
the relationship between CVD and VaD has been well documented (Alonso et al., 2009; Fillit 
et al., 2008; Morovic et al., 2009; Whitmer et al., 2005; see review by Patterson et al., 2007). 
Stroke, either symptomatic or silent, is commonly associated with VaD and is used as a 
diagnostic criterion (Hachinski et al., 1975; see reviews by Patterson et al., 2007). The 
occurrence of silent strokes increases dramatically as an individual ages: from 5% at 60 years 
of age, to 35% at 90 years of age (Price et al., 1997; Vermeer et al., 2002; 2003a). Although 
symptomatic strokes cause more physical damage to the brain than asymptomatic or silent 
strokes, these silent strokes (included in brain infarcts) are dangerous as they, by definition, 
have no outward symptoms to indicate that a stroke has occurred. Individuals who have had 
silent strokes may appear healthy otherwise, but are at an increased risk of developing 
dementia and will experience a steeper decline in cognitive function than older adults 
without silent strokes (Vermeer et al., 2003a,b). 
 As stated previously, hypertension is a risk factor for dementia, including VaD 
(Hebert et al., 2000; Lindsay, Hebert & Rockwood, 1997; Nagai, Hoshide & Kario, 2010). 
Cardiovascular diseases including coronary artery disease, heart disease, atherosclerosis and 
heart failure have also been found to be risk factors for VaD (Hebert et al., 2000; Lindsay, 
Hebert & Rockwood, 1997; Nagai, Hoshide & Kario, 2010; see reviews by Duron & Hanon, 









Diabetes mellitus has been found to be a significant risk factor for VaD (Hebert et al., 
2000; MacKnight et al., 2002; Saczynski et al., 2008; see reviews by Launer, 2009; Patterson 
et al., 2007). Using CSHA data, Hebert et al. (2000) observed a significant odds ratio of 2.15 
for diabetes in those diagnosed with VaD. Therefore, those with VaD were twice as likely to 
be diabetic. However, diabetes is closely associated with many vascular risk factors, such as 
increased BMI, which may mediate this relationship. 
 
2.1.3.3.3.3. Depression 
 Having a history of depression has been shown to be associated with VaD (Hebert et 
al., 2000; Katzman et al., 1989). Using CSHA data, Hebert et al. (2000) found that 
depressive symptoms preceded the development of VaD, suggesting that depression may be 




Dementia is a neurodegenerative disease that results in impairment of cognitive 
function. Dementia results from various disease processes within the brain, ranging from 
Parkinson’s to alcohol abuse. As the two major subtypes of dementia are AD and VaD, their 






2.1.4.2. Alzheimer’s Disease 
Classic AD is characterized by three major hallmarks: senile plaques, neurofibrillary 
tangles and cholinergic deficiency (see reviews by Cummings, 2004; Cummings et al., 1998; 
Fisher, 2007). These are associated with neurodegeneration, atrophy and subsequent 
cognitive impairment. 
Senile plaques are caused by the production and accumulation of beta-amyloid (Aβ) 
peptide (see review by Cummings, 2004). The Aβ peptide is made up of 40 to 42 amino 
acids and results from the cleavage of a larger amyloid precursor protein (APP). In a normal 
functioning brain, APP is critical to neural growth, survival and post neural injury repair (see 
reviews by Cummings, 2004; Querfurth & Laferla, 2010). In an AD brain, APP has been 
stimulated to be cleaved into small pieces (Aβ) through the successive action of two 
enzymes, β and γ secretase, respectively generating the N-terminus and C-terminus (see 
reviews by Cummings, 2004; Keller, 2006; Querfurth & Laferla, 2010). Aβ then accumulates 
to form various forms of plaques that are associated with AD neuropathology (see reviews by 
Cummings, 2004; Querfurth & Laferla, 2010). Senile plaques, which include diffuse plaques 
and classic neuritic plaques, are differentiated based on their appearance (see reviews by 
Cummings, 2004; Querfurth & Laferla, 2010).  
Neurofibrillary tangles are proteinaceous structures made up of hyperphosphorylated 
tau protein (see reviews by Cummings, 1998; Keller, 2006; Querfurth & Laferla, 2010). Tau 
is a stabilizer protein, which aids in the internal support structure of neurons. Specifically, 
tau protein stabilizes microtubules within the cytoskeleton structure when phosphorylated 
(see review by Cummings et al., 1998). In an AD brain, however, tau becomes 





Querfurth & Laferla, 2010). The distribution of tangles within the brain occurs in a 
systematic manner. This pattern correlates with early symptoms of memory impairment seen 
in AD patients and subsequent symptom progression (see review by Cummings et al., 1998). 
Both plaques and tangles disrupt normal neuronal and synaptic functioning, causing cell 
death and brain atrophy. 
A major biochemical hallmark of Alzheimer’s disease is cholinergic deficiency, 
including reduced choline uptake, reduced acetylcholine release and degeneration of 
cholinergic neurons (see review by Francis et al., 1999). The role of cholinergic 
neurotransmission in memory led to increased research into cholinergic deficiencies and their 
possible contribution to cognitive dysfunction and decline seen in AD individuals (see 
reviews by Francis et al., 1999; Querfurth & Laferla, 2010; Tyas & Gutmanis, 2008). These 
cholinergic deficiencies may affect aggregation of amyloid, leading to neuroinflammation 
(see reviews by Querfurth & Laferla, 2010; Salminen et al., 2009; Shen, 2004; Wenk, 2003). 
Aβ is neurotoxic to nicotinic acetylcholine receptors and impairs their signalling, in addition 
to reducing acetylcholine release from the presynaptic terminal (see reviews by Buckingham 
et al, 2009; Querfurth & Laferla, 2010). Since cholinergic deficits were the first 
neurotransmitter system impairment identified in relation to AD, many forms of AD 
treatments have been based on alleviating this deficiency (see review by Burns, 2009). 
Although the cholinergic system has been a focus of AD research, other neurotransmitter 
deficiencies have also been identified and are the basis of other treatment strategies, such as 
NMDA-receptor agonists (see reviews by Blennow, de Leon & Zetterberg, 2006; Tyas & 
Gutmanis, 2008). There are various other treatment strategies for AD, to address either 





modulators, Aβ immunotherapy, anti-tau and anti-inflammatory medication) (see reviews by 
Blennow, de Leon & Zetterberg, 2006; Cummings, 2004). 
 
2.1.4.3. Vascular Dementia 
VaD is characterized by vascular injury in the brain. The terms multi-infarct 
encephalopathy and post-ischemic lesions describe overall neurovascular injury (see review 
by Jellinger, 2008). Vascular injury can be categorized as focal, multifocal or diffuse lesions. 
Lesions can then be further sub-categorized by size or location. For instance, lacunes are 
larger than micro-infarcts, while white matter lesions and hippocampal sclerosis describe 
specific locations of lesions in the brain. Lesions can also be distinguished based on whether 
they are related to large or small vessel disease (see review by Jellinger, 2008). The above 
types of vascular injury are the result of systemic, cardiac, local large or small vessel disease 
(see review by Jellinger, 2008). However, the type of lesion in the brain may not be as 
important as the volume of brain destroyed or the location or number of vascular lesions (see 
review by Jellinger 2008). Specifically, strategic locations of vascular injury, even when 
small in size, can cause more damage than larger lesions in ‘unimportant’ areas of the brain. 
Stroke and silent stroke are often the cause of vascular injury in the brain (Vermeer et al., 
2003). Vascular events in the brain cause a cascade of events to occur, such as hypoxia, 
neuroinflammation and oxidative stress (see reviews by Jellinger, 2008; Querfurth & Laferla, 







2.1.4.4. Mixed Dementia 
AD has many vascular components in addition to traditional AD pathology. Mixed 
dementia is diagnosed when a patient has evidence of AD plus cerebrovascular disease or 
vascular encephalopathy, which is identified based on neuroimaging or the occurrence of an 
ischemic event, such as stroke (see reviews by Jellinger, 2008; Kalaria, 2002). The overlap 
between neurodegenerative burden (i.e., pure AD) and vascular cerebral lesion burden (i.e., 
pure VaD) results in mixed dementia. It has been suggested that the overlap between AD and 
VaD neuropathology should be viewed as a continuum or spectrum of dementia (see review 
by Viswanathan, Rocca & Tzourio, 2009).  
 
2.1.4.5. Mild Cognitive Impairments 
 The neuropathophysiology of CIND or MCI can be described as a mild version of 
dementia neuropathophysiology, such as that found in the very early stages of AD or VaD 
(Bennett et al., 2005; Markesbery et al., 2006). In those suffering from MCI or CIND, the 
burden of plaques and tangles or vascular lesions in the brain has not yet reached the critical 
threshold necessary for dementia (Markesbery et al., 2006; Schneider et al., 2009). In their 
study examining the various neuropathologies of those diagnosed with MCI, Bennett et al. 
(2005) found that nearly all persons had some level of AD pathology and 35% of people also 
had cerebral infarcts. It has also been suggested that neurofibrillary tangle density is 
important when determining the stage of MCI and whether it will progress to AD (Guillozet 
et al., 2003). Not all cases of MCI or CIND, however, will progress to a more severe form of 







2.2.1.1. Headache Disorders 
The most common form of neurological disorder is a headache, which causes 
substantial disability in the population (Stovner et al., 2007; see review by O’Bryant et al., 
2006). There are two broad groups of headache disorders: primary and secondary. Primary 
headache disorders are those where the headache is the primary problem. Conversely, 
secondary headache disorders are those that are caused by an underlying condition, such as a 
brain tumour or head injury (see review by Lipton, Hamelsky & Stewart, 2004). Migraines 
are one of the most common forms of primary headache disorders and are considered to be 
one of the most debilitating (see review by Lipton, Hamelsky & Stewart, 2004). 
Migraines differ from other types of headaches in a number of ways, such as altered 
visual perception, phonophobia (sound sensitivity), photophobia (light sensitivity) and 
nausea (see review by Lipton, Hamelsky & Stewart, 2004). There are two distinct types of 
migraines defined by the International Headache Society (IHS) using the second edition of 
the International Classification of Headache Disorders (ICHD-II): migraines with aura (MA) 
and migraines without aura (MoA) (Silberstein et al., 2007; see reviews by Lipton & Bigal, 
2005; Lipton, Hamelsky & Stewart, 2004).  
 
2.2.1.2. Phases of a Migraine Attack 
A migraine attack can be broken down into four phases: prodrome or premonitory, 
aura, pain or headache, and postdrome or resolution (see review by Lipton, Hamelsky & 





experienced may vary for each migraine attack, as well as the accompanying symptoms. 
Prodromal symptoms usually occur hours or days before a migraine attack and can include 
altered mood, excessive sleepiness, cravings or stiff muscles (see reviews by Lipton, 
Hamelsky & Stewart, 2004; Silberstein, Lipton & Goadsby, 1998). Only about 40-60% of 
migraineurs suffer from prodromal symptoms. Aura is a neurological phenomenon that 
precedes or accompanies a migraine attack and can last from five minutes to an hour. Aura 
symptoms can be visual, motor or sensory: the most common form is visual aura. Visual aura 
may include a variety of positive features (e.g., seeing spots) and negative features (e.g., 
areas of visual loss) (see review by Lipton, Hamelsky & Stewart, 2004). Twenty to thirty 
percent of migraineurs suffer from MA. Individuals who suffer from MA often will also have 
MoA. The headache or pain phase usually follows aura. It is characterized by throbbing on 
one side of the head, which can range from moderate to severe intensity (see review by 
Lipton, Hamelsky & Stewart, 2004). The headache phase is often accompanied by 
photophobia, phonophobia, nausea and vomiting (see review by Lipton, Hamelsky & 
Stewart, 2004). During the resolution or postdromal phase, migraine pain and accompanying 
symptoms begin to subside. However, many migraineurs report suffering from long-term 
physical and psychological symptoms that can last for days or weeks (e.g., scalp tenderness 
or mood changes) (see review by Lipton, Hamelsky & Stewart, 2004). 
 
2.2.1.3. Probable Migraine 
Many people who report migraine-like features will fail to fully meet the criteria of 
the IHS: ICHD-II for either MA or MoA. This condition has become known as “probable 





Silberstein et al., 2007; see reviews by Bigal, Lipton & Stewart, 2004; Lipton & Bigal, 
2005). According to the IHS: ICHD-II, a probable migraine diagnosis is applicable when the 
individual meets all but one criterion for MA or MoA (Patel et al., 2004; Silberstein et al., 
2007; see review by Bigal, Lipton & Stewart, 2004). Research suggests that the profile of a 
migraine changes over the course of an individual’s life. This suggests that since the profile 
of a migraine varies over a lifetime, not all individuals suffering from probable migraine will 
progress to full migraine; although some may progress to a full migraine diagnosis, others 
will cease to experience migraines at all (see review by Bigal, Liberman & Lipton, 2006).  
 
2.2.1.4. Diagnostic Criteria 
Migraine diagnoses are based on an exclusion-inclusion standard. The IHS: ICHD-II 
diagnostic criteria are the gold standard of migraine diagnosis (IHS:ICHD, 1988; IHS:ICHD, 
1997; 2004; Silberstein et al., 2007; see reviews by Lipton & Bigal, 2005; Lipton, Hamelsky 
& Stewart, 2004). Migraine diagnosis rates may be inaccurate because many individuals do 
not consult doctors or receive medical diagnoses for their migraine disorder (see review by 
Bigal, Lipton & Stewart, 2004). Lipton, Diamond et al. (2001) found that although migraine 
diagnoses have increased, approximately half of the population in the US suffering from 
migraines remains undiagnosed. Also, individuals who do not meet MA or MoA diagnostic 
criteria may meet the criteria for probable migraine (Patel et al., 2004; Silberstein et al., 
2007; see review by Bigal, Lipton & Stewart, 2004). Migraine headache studies often use 
self-reported migraine history, rather than the IHS: ICHD criteria diagnoses. Research has 
shown that there is excellent agreement between questionnaire-based self-reported migraine 





when the questionnaire items have been modified from IHS: ICHD-II criteria questions, high 
sensitivity and specificity have been observed in validation studies among population 
samples (Schurks, Buring & Kurth, 2009; Lipton et al., 2001). 
 
2.2.2. Rates and Impact on the Population 
2.2.2.1. Incidence and Prevalence 
Migraines affect approximately 11% of people experiencing a headache disorder 
(Stovner et al., 2007). It is estimated that 35 million people in the US suffer from severe 
migraine headaches (Diamond et al., 2007; see review by Bigal & Lipton, 2009). In Canada, 
it is estimated that four million people suffer from migraines (O’Brien, Goeree & Streiner, 
1994; see review by Becker, Gladstone & Aube, 2007). 
Both migraine incidence and prevalence vary by gender and age (see reviews by 
Bigal & Lipton, 2009; Diener & Beck, 2009; Lipton & Bigal, 2005a,b). Migraine rates vary 
by gender, affecting up to 20% of women and 8% of men globally (see review by Diener & 
Beck, 2009). Cumulative lifetime incidence of migraines has been found to be 43% in 
women and only 18% in men (Stewart et al., 2008). The incidence of MA is highest in 
females between the ages of 12 and 13, whereas incidence of MoA is highest in females 
between the ages of 14 and 17 (see reviews by Bigal & Lipton, 2009; Lipton & Bigal, 
2005a,b). Incidence of both types of migraines peaks earlier for males: approximately 5 years 
of age for MA and 10 to 11 years of age for MoA (see reviews by Bigal & Lipton, 2009; 
Lipton & Bigal, 2005a,b). Prior to puberty, migraine prevalence is higher in boys than in 
girls, but as adolescence approaches, both incidence and prevalence increase more rapidly in 





prevalence of migraines among women increases throughout childhood and early adulthood 
until approximately age 40, when it declines (see reviews by Bigal & Lipton, 2009; Lipton & 
Bigal, 2005a,b). The overall prevalence of migraine is higher in women than in men (see 
reviews by Bigal & Lipton, 2009; Lipton & Bigal, 2005a,b). For both men and women, 
overall migraine prevalence is highest from the ages of 25 to 55, which corresponds to the 
peak years of economic productivity (see reviews by Bigal & Lipton, 2009; Lipton & Bigal, 
2005a,b). The gap between peak incidence in adolescence and peak prevalence in mid-life 
reflects the chronic nature of migraines (see review by Bigal & Lipton, 2009). Migraine 
prevalence does appear to decline in post-menopausal women. Some studies, however, have 
shown that a small number of women experience a worsening of symptoms or no change at 
all in their migraine status (MacGregor, 2009).  
In addition to age and gender differences in migraine prevalence and incidence, 
variation also occurs with race and geographic location (see review by Bigal & Lipton, 
2009). The highest prevalence estimates have been found in North America. Within North 
America, Caucasian Americans experience the highest migraine prevalence, followed by 
African Americans, with the lowest prevalence seen in Asian Americans (Stewart et al., 
1992, 1995, 1996; see review by Bigal & Lipton, 2009). Prevalence estimates are also low in 
Asia and Africa and continue to be low in North America for Asian and African-Americans. 
Researchers speculate that this implies a race-related genetic susceptibility for migraines 
(Stewart et al., 1996).  
In addition to variation by race, migraine prevalence also varies by socioeconomic 
status. In the US, it has been shown that migraine prevalence is inversely related to 





& Bigal, 2005a,b; Lipton et al., 2007), with low socioeconomic status, income or education 
related to an increased prevalence of migraines. This relationship is observed in adults and 
those without a family history or predisposition for migraines (Bigal et al., 2007). Bigal et al. 
(2007) noted that among adolescents with a family history of migraines, the relationship 
between household income and migraine prevalence was not significant. Bigal et al. (2007) 
speculated that this might be due to an increased biological predisposition: in those with a 
family history of migraines, a genetic predisposition may be more influential in causing 
migraines than environmental or socioeconomic factors. 
 
2.2.2.2. Impact of Migraines 
The burden of headache disorders on individuals and society is much greater than 
previously thought. The medical community is beginning to change its attitude towards 
headache disorders and specifically migraines, with the recognition that migraines are the 
cause of significant suffering, disability and impairments in quality of life (see review by 
Leonardi, 2005). This change in attitude may be in part due to the World Health 
Organization (WHO) acknowledging headache disorders as a high-priority public health 
issue as stated in the World Health Report 2001 (WHR, 2001). The WHO ranked migraine as 
the 19th cause of disability in both sexes and the 12th for women alone (Stovner et al., 2007; 
WHR, 2001; see review by Leonardi et al., 2005). 
In the US, 25% of female migraine sufferers experience more than four severe 
migraine attacks per month and 35% experience one to four severe attacks per month 
(Lipton, Stewart et al., 2001; see reviews by Bigal & Lipton, 2009; Lipton & Bigal, 2005a,b; 





condition to manage, as an individual cannot always predict when a migraine attack will 
occur. This unpredictability can have adverse effects on an individual’s psychological well-
being. In particular, migraine sufferers report fear of their migraine condition disrupting their 
work and making them unable to care for themselves and others (see reviews by Bigal & 
Lipton, 2009; Lipton & Bigal 2005a,b; Lipton et al. 2003). Health-related quality of life 
(HRQoL) disability measures have been used to assess the impact of migraine on an 
individual. Many studies have shown that migraine reduces an individual’s HRQoL not only 
during a migraine attack, but also prior to and following the attack (El Hasnaoui et al., 2003; 
see reviews by Bigal & Lipton, 2009; Lipton & Bigal, 2005a,b; Lipton et al., 2003, 2000). 
The issue of comorbid disorders is also a major concern for those suffering from migraines, 
as a comorbid disorder may cause added disability. Migraine sufferers are more likely to also 
suffer from vascular diseases or disorders (e.g., hypertension or diabetes) (Bigal et al., 2009; 
see reviews by Bigal et al., 2010; Scher et al., 2005). In addition, migraine medication is 
often expensive and may have side effects that cause further disability for the individual, 
such as insomnia (Bigal et al., 2007). 
Migraines not only impact the individual in the form of disability, but also impact 
society. Direct costs of migraine can be quantified through the economic value of the 
disorder in relation to health care utilization (see reviews by Bigal & Lipton, 2009; Lipton & 
Bigal, 2005a,b; Lipton et al., 2003, 2000). Migraines increase the use of emergency 
departments and urgent care centers, in addition to prescription and over the counter 
medications. The indirect cost of migraine is primarily made up of loss of productivity due to 
absenteeism and reduced work performance while at work (Hu et al. 1999). Hu et al. (1999) 





2.2.2.4. Probable Migraine 
Probable migraine shares a similar epidemiologic pattern with conventional 
migraines (Patel et al., 2004; Silberstein et al., 2007). However, prevalence estimates for 
probable migraine vary widely, ranging from 2.6% to 14.5% (Henry et al., 2002; Lipton, 
Stewart et al., 2001; Patel et al., 2004; Silberstein et al., 2007). These estimates vary due to 
under-diagnosis of probable migraine, as well as underestimates due to lack of self-report. 
Prevalence of probable migraine is slightly higher in women than in men (Henry et al., 2002; 
Lipton, Stewart et al., 2001; Patel et al., 2004; Silberstein et al., 2007). In both men and 
women, probable migraine prevalence peaks during mid-life, between the ages of 30 and 59 
years (Patel et al., 2004; Silberstein et al., 2007). Race-specific differences have been 
observed for probable migraine as well as classic migraine (Silberstein et al., 2007). In 
contrast to migraine, probable migraine prevalence is higher in African-Americans than in 
Caucasian Americans (Silberstein et al., 2007). However, in an earlier study, probable 
migraine prevalence in different races mimicked estimates seen for migraine (Patel et al., 
2004). Individuals suffering from probable migraine experience disability and loss of quality 
of life similar to those suffering from migraines (Patel et al., 2004; Silberstein et al., 2007). 
 
2.2.3. Risk Factors, Triggers and Comorbidities 
2.2.3.1. Definition of Risk Factors, Triggers and Comorbidities 
It is important to distinguish between risk factors, triggers and comorbidities of 
migraine. A migraine risk factor increases the risk of an individual developing migraine, 
whereas a migraine trigger induces or precipitates a migraine attack in a migraine sufferer. 





disorders with migraine, within the same individual. A summary of risk factors, triggers and 







Table 2: Risk factors, triggers and comorbidities for headache disorders 
 
 Migraine (MA1/MoA2) Probable Migraine 




Low socioeconomic status 







- Activity level 
Physiological 





- Panic disorders 
- Anxiety 
- Depression 
- Bipolar disorder 
Neurological 
- Chronic pain disorders 
- Epilepsy 
- Tourette's syndrome 
Vascular 




- Family history of 
myocardial infarction 





1MA- migraines with aura 
2MoA- migraines without aura 
3Risk factors increase the risk of an individual developing migraine 
4Triggers induce or precipitate a migraine attack in a migraine sufferer 
5Comorbidities are the greater than coincidental association of separate diseases or disorders 






2.2.3.2. Risk Factors 
Migraine risk factors are often difficult to identify, as they are occasionally mistaken 
for triggers. Migraine risk factors include female gender, family history of migraines, 
depression, epilepsy and low socioeconomic status (Bigal et al., 2007; Breslau et al., 2003; 
see reviews by Breslau & Rasmussen, 2001; Lipton, Hamelsky & Stewart, 2004). 
Female gender is one of the most consistent risk factors for migraines, given that 
migraines affect up to 20% of women and only 8% of men globally (see review by Diener & 
Beck, 2009). The exact pathophysiological reason for this relationship between migraine 
incidence, prevalence and female gender is not known, although researchers have suggested 
that it is related to menstrual cycle hormones, specifically estrogen (MacGregor, 2009). 
Given that family history of migraine is a risk factor for migraine, many researchers 
have speculated that there is a genetic component involved in migraine risk (see review by 
Breslau & Rasmussen, 2001). Certain rare forms of inherited migraine disorders have been 
linked to genetic factors: chromosomes 1 and 19 have specifically been identified (see 
review by Breslau & Rasmussen, 2001; Montagna, 2008). Despite some genes being 
implicated in inherited migraines, migraines are not inherited in a straightforward manner. 
Research suggests that although genetics play a part in inherited migraines, a multi-factorial 
inheritance pattern (multiple genes interacting with various environmental factors) is most 
likely (see review by Breslau & Rasmussen, 2001; Montagna, 2008). It is also possible that 
genetic factors may affect the association between migraines and cognitive health outcomes. 
Research on both migraines and AD has implicated chromosomes 1 and 19 (Azad, Al 





Breslau & Rasmussen, 2001; Burns & Iliffe, 2009; Patterson et al., 2007). This genetic 
relationship has not been thoroughly investigated (Lopera et al., 1997; Ringman et al., 2008). 
Major depression has been shown to increase the risk of migraine, and migraine 
increases the risk for major depression (Breslau et al., 2003). Patel et al. (2004) found the 
overall prevalence of major depression to be 29.1% for migraine (MoA/MA), 19.5% for 
probable migraine and 23.1% for both migraine and probable migraine pooled together, 
compared to controls with only 10.3% prevalence of depression. 
Epilepsy may be considered a risk factor for migraines, but also a comorbidity. 
Epilepsy can cause migraines; conversely, migraines can cause epileptic seizures (see 
reviews by Bigal et al., 2003; Diener, Kuper & Kurth, 2008). When a migraine headache 
precipitates an epileptic seizure, it is referred to as migralepsy (see review by Bigal et al., 
2003). Alternatively, an epileptic seizure can trigger a migraine headache; this is often 
referred to as a post-seizure headache (see reviews by Bigal et al., 2003). The relationship 
between migraines and epilepsy is often mis- or under-diagnosed (see reviews by Bigal et al., 
2003; Diener, Kuper & Kurth, 2008). Incidence of migraine is 2.4 times higher in people 
with epilepsy (see review by Diener, Kuper & Kurth, 2008). The relationship between 
migraines and epilepsy is due to the overlapping biological mechanisms in the brain (see 
reviews by Bigal et al., 2003; Diener, Kuper & Kurth, 2008). One such mechanism is cortical 
spreading depression, which is a wave of depolarization that propagates across the brain 
cortex, initiating excitation followed by depression of normal neuronal activity (Welch, 







Migraine triggers vary depending on the individual. They can be classified as 
endogenous or exogenous factors (see reviews by Breslau & Rasmussen, 2001; Lipton, 
Hamelsky & Stewart, 2004). Endogenous factors include those that originate within the 
migraine sufferer, such as hormone cycles (see reviews by Breslau & Rasmussen, 2001; 
Lipton, Hamelsky & Stewart, 2004). Exogenous factors are those that affect an individual 
from outside, for example, diet, activity level, foods or even certain smells (see reviews by 
Breslau & Rasmussen, 2001; Lipton, Hamelsky & Stewart, 2004). Triggers are often 
separated into subcategories, such as dietary, environmental, behavioural, physiological or 
psychological factors (see review by Lipton, Hamelsky & Stewart, 2004). 
 
2.2.3.4. Comorbidities 
Migraine comorbidities can cause confusion if they are not classified accurately, 
creating misleading research results and missed opportunities to treat or prevent the 
conditions involved (see review by Bigal & Lipton, 2009). Comorbidities of migraine are 
most often categorized as psychiatric, neurological, or vascular (see reviews by Bigal & 
Lipton, 2009; Scher, Bigal & Lipton, 2005). Migraine has been found to be comorbid with 
various psychiatric disorders, including panic disorders, anxiety, depression and bipolar 
disorder (see reviews by Bigal & Lipton, 2009; Scher, Bigal & Lipton, 2009). Neurological 
disorders that have been associated with migraine include epilepsy and Tourette’s syndrome 
(see reviews by Bigal & Lipton, 2009; Scher, Bigal & Lipton, 2009). Other disorders that 





defects, asthma, allergies and chronic pain disorders (see reviews by Bigal & Lipton, 2009; 
Scher, Bigal & Lipton, 2009).  
The comorbid association between migraines and CVD has become a major research 
focus, as CVD is the leading cause of death in North America (WHO, 2002). Migraine 
sufferers have a higher prevalence of risk factors that are associated with CVD, such as 
diabetes, hypertension, hyperlipidemia and family history of myocardial infarction (Bigal et 
al., 2009; see reviews by Bigal et al., 2010; Scher et al., 2005). Migraine is associated with 
vascular events as well, such as myocardial infarction and stroke (Bigal et al., 2010; see 
reviews by Bigal et al., 2009; Scher, Bigal & Lipton, 2005). The association between 
migraine and stroke has been well documented, specifically MA and stroke. The relationship 
between migraine and CVD, including stroke, appears to be strongest in women (Kurth et al., 






2.2.4.1. Neuropathophysiology of Triggers 
The exact mechanism by which migraine triggers initiate migraine attacks is 
unknown. However, researchers have hypothesized that migraine sufferers are genetically 
predisposed to a hyper-excitable or under-inhibited cortex (Chakravarty, 2010; see review by 
Lambert & Zaqgami, 2008). The migraine trigger is thought to elicit a response in 
individuals with a low migraine threshold, which precipitates cortical discharges that give 
way to cortical spreading depression (CSD) (Chakravarty, 2010). Triggers are in essence a 
cortical phenomenon, as they can be viewed as sensations (Chakravarty, 2010). Triggers 
reach the cortex through sensory pathways (i.e., sight, smell, sound) or humorally through 
the blood stream (i.e., hormones, absorbed chemicals). Upon reaching the cortex, triggers 
may act by altering ionic flow across cell membranes, inducing CSD in an already hyper-
excitable cortex (Chakravarty, 2010). 
 
2.2.4.2. Acute Neuropathophysiology of Migraines 
The major underlying biological mechanisms involved in migraine disorders include 
CSD, neural inflammation, and cranial vascular contraction and expansion. The same general 
pathophysiology occurs in both MA and MoA. Several areas and pathways within the brain 
are involved in the underlying mechanism of migraine headaches and vary based on the 
migraine phase. 
The underlying mechanism of aura is CSD, which is a wave of depolarization that 
propagates across the brain cortex, initiating excitation followed by depression of normal 





cerebral blood flow (Welch, Michael & Goadsby, 2003). CSD activates the trigemino-
vascular system, which induces neurogenic inflammation due to the release of vasoactive 
peptides, specifically substance P and calcitonin gene-related peptide (see reviews by Buzzi 
& Moskowitz, 2005; Panconesi, Bartolozzi & Guidi, 2009). A transient increase in regional 
cerebral blood flow (vasodilation) is followed by a long-lasting considerable decrease in 
regional cerebral blood flow (vasoconstriction) (see review by Hamed, 2009). These events 
are sometimes referred to as spreading hypoperfusion. 
A migraine moves from the aura phase to the headache or pain phase due to 
spreading depression causing stimulation of the trigeminal nucleus caudalis. The wave of 
cortical excitation and depression activates cortical-subcortical connections to nociceptive 
centers. Headache pain is due to the dilation of blood vessels caused by trigemino-vascular 
system activation, specifically stimulation of large cranial vessels and dura mater (see review 
by Hamed, 2009). This is in response to neural inflammation, which involves both 
vasodilation and plasma protein extravasation (i.e., leakage) that occurs in areas innervated 
by the trigemino-vascular system (see review by Buzzi & Moskowitz, 2005). Since CSD 
activates the trigemino-vascular system and causes a cascade of events leading to 
inflammation, this can become a persistent source of trigeminal stimulation and headache 
pain (Welch, Michael & Goadsby, 2003). The postdrome phase occurs when the headache 
pain and accompanying symptoms are subsiding due to decreasing inflammation in the brain 






2.2.4.3. Chronic Neuropathophysiology of Migraines 
Repeated migraine attacks can cause long-term neurological damage, such as 
vascular injury and chronic inflammation (see reviews by Hamed, 2009; Panconesi, 
Bartolozzi & Guidi, 2009). Migraines cause changes in cranial vasculature: after the 
migraine attack has subsided, intracranial arteries have been seen to narrow. Various 
inflammatory markers have been observed in those suffering from chronic migraines. These 
markers include increased levels of C-reactive protein, interleukins (e.g. IL-1 and IL-6), 
tumour necrosis factor-alpha, and adhesion molecules (inter-cellular adhesion molecule and 
vascular cell adhesion molecules), which are markers for inflammation, oxidative stress, 
disturbed aggregability of the blood cells and thrombosis (see review by Hamed, 2009). 
Repeated vascular inflammation can thus result in endothelial injury of blood vessels, 
arteriopathy and thrombosis (see reviews by Hamed, 2009; Panconesi, Bartolozzi & Guidi, 
2009). Vascular and ischemic injury has been shown to be associated with increased risk of 
stroke (Kurth et al., 2005; see review by Kurth & Diener, 2006). Hamed et al. (2010) 
concluded that endothelial injury, impaired endothelial vasoreactivity and increased carotid 
artery intima-media thickness occur with migraine. These vascular conditions are associated 
with various vascular risk factors and subsequently increase the risk of atherosclerosis 
(Hamed et al., 2010; 2009). These results suggest that migraines cause significant vascular 






2.3. Migraines and Late-life Cognitive Health Outcomes 
2.3.1. Migraines and Cognitive Impairment 
Research regarding the relationship between migraines and cognitive function has 
produced conflicting results. Migraines have been shown to have deleterious effects on 
cognitive skills including attention, verbal ability, verbal and visual memory, and 
psychomotor ability (Calandre et al., 2002; D’Andrea et al., 1989; Hooker & Raskin, 1986; 
Le Pira et al., 2004, 2000; Mulder et al., 1999; Scherer, Bauer & Baum, 1997; Waldie et al., 
2002; Zeitlin & Oddy, 1984). However, other studies have shown no differences in cognitive 
performance in those suffering from chronic migraines (Baars, Boxtel & Jolles, 2010; Bell et 
al., 1999; Burker, Hannay & Halsey, 1989; Gaist et al., 2005; Jelicic et al., 2000; Leijdekkers 
et al., 1990; Pearson et al., 2006). Variation in study results may be due to the variety of age 
groups studied, as well as the various cognitive performance tests utilized. Cognitive skills 
and performance tests used range from the Boston Scanning Test, which assesses conceptual 
abilities, to the California Verbal Learning Test, which assesses verbal memory and learning 
strategies. The age groups used in previous studies vary; few have looked at older adults. See 
Appendix A for a comparison of similarities and differences between the above studies. 
Researchers have found an association between migraines and below average 
cognitive performance during mid-life (Le Pira et al., 2000; Waldie et al., 2007; Zetlin & 
Oddy, 1984; see review by Paemeleire, 2009). However, there is still controversy over the 
possible relationship between migraines and cognitive decline (Calandre et al., 2002; 
Kalaydjian et al., 2007; Pearson et al., 2005; see reviews by Paemeleire, 2009). Kalaydjian et 
al. (2007) observed that migraine sufferers’ performance scores on cognitive tests were 





migraine on cognitive tests were only seen in those over the age of 50 years (Kalaydjian et 
al., 2007). 
 
2.3.2. Epidemiologic Studies of Migraines and Dementia 
There have been very few epidemiological studies that have investigated the 
relationship between migraines and cognitive health outcomes. The majority of 
epidemiological studies focus on the relationship between migraines and cognitive 
performance (i.e., cognitive test scores), rather than a broader cognitive health outcome in 
late-life, such as dementia.  
Only two studies have investigated the relationship between migraines and dementia, 
specifically AD. Using the MSHA dataset, Tyas et al. (2001) reported that migraines 
increased the risk of AD (Relative Risk (RR)=3.49, 95% CI:1.39-8.77); an even stronger 
effect was observed in women (RR=5.78, 95% CI:2.00-16.74). Tyas et al. (2001) adjusted 
for age, education and sex. However, these results disagree with a meta-analysis of eight 
case-control studies performed 10 years earlier (Breteler et al., 1991), although only four of 
the eight case-control studies contained data on migraines. Interestingly, one study included 
in the meta-analysis reported a non-significant higher risk for those with headaches; 
OR=1.60, 95% CI:0.48-5.61 (French et al., 1985). Breteler et al. (1991) found an inverse 
relationship between AD risk and migraines (RR=0.7, 95% CI:0.5-1.0). However, Breteler et 
al. (1991) saw an increased risk in men (RR=1.1, 95% CI:0.6-2.0) compared to women 
(RR=0.6, 95% CI:0.4-0.9). In contrast to Tyas et al. (2001), Breteler et al. (1991) only 





A relationship between migraines and vascular dementia has been hypothesized 
because of the relationship between migraines and various vascular risk factors and health 
outcomes, such as stroke or heart attack. However, no epidemiologic study has been done to 
investigate this relationship (see review by Paemeleire, 2009). 
 
2.3.3. Biological Mechanism Linking Migraines and Late-life Cognitive Health 
Outcomes 
Migraines are a risk factor for various diseases and disorders, such as stroke and CVD 
(Scher et al., 2009; see review by Kurth et al., 2009). The reason for this may be the overlap 
of disease pathologies and underlying biological mechanisms. Many of the mechanisms 
involved in migraine neurophysiology, such as inflammation and reduced cerebral blood 
flow, are also underlying causes of dementia (Peers et al., 2009; see reviews by Hamed, 
2009; McGeer, Rogers & McGeer, 2006; Panconesi, Bartolozzi & Guidi, 2009). Repeated 
exposure to these mechanisms, due to chronic migraine attacks, has been shown to cause 
permanent neurological damage (see review by Hamed, 2009). Levels of neurological 
damage may be related to the intensity, severity and frequency of migraine attacks; the 
varying levels of neurological damage may be similarly correlated with levels of dementia or 
cognitive decline (Calandre et al., 2002; see review by O’Bryant et al., 2006).  
The overlap between the underlying biological mechanisms of both migraines and 
dementia suggests that having a history of migraines may increase the risk for negative 
cognitive health outcomes in late life. A hypothesized biological mechanism linking 



























2.3.3.1 Description of Variable Types 
To address the hypothesized biological mechanism linking migraine and cognitive 
impairment, variables were analyzed as confounding variables, intervening variables, or 
effect modifiers, based on evidence from the literature on each variable’s relationship to the 
exposure and outcome.  
Confounding variables are related to both the exposure and the outcome variables, 
but are not on the casual pathway between the exposure and outcome (see reviews by 
Kraemer et al, 2001; Last, 2001). Unless a confounding variable is addressed by adjusting in 
multivariate analyses or use of other strategies, its effects may distort the effects of the 
exposure under investigation on the outcome (see reviews by Kraemer et al, 2001; Last, 
2001). An example of how confounding may apply to this thesis project can be seen when 
examining the effects of sex on the association between migraines and AD. Female sex 
increases the risk of migraines and AD and is not along the causal pathway between 
migraines and AD. Therefore, if the potential confounding effects of sex are not addressed, 
any relationship observed between migraines and AD may be incorrect and alternatively 
explained by the relationship between AD and sex. The possible confounding variables to be 
examined were age, sex, education, depression and epilepsy. These variables have been 
shown in the literature to be related to the exposure, migraines, and the outcome, late-life 
cognitive health.  
Alternatively, intervening variables or mediators are variables that are related to the 
causal pathway between the exposure and outcome variables (see reviews by Kraemer et al, 
2001; Baron & Kenny, 1986). An intervening variable can cause variation in how the 





Intervening variables are statistically associated with the outcome variable (Last, 2001). 
Potential intervening variables to be examined were hypertension, diabetes, stroke, 
myocardial infarction and other heart conditions. These variables have been hypothesized to 
be related to the pathway connecting the exposure, migraines, and the outcome, late-life 
cognitive health outcomes. 
In addition to confounding and intervening variables, this thesis project will also be 
addressing effect modifiers. An effect modifier modifies the effect of the exposure variable 
on the outcome (see reviews by Kraemer et al, 2001; Last, 2001). Effect modifiers are often 
observed as subgroups within which the relationship between the exposure and the outcome 
varies. The association between migraines and late-life cognitive health outcomes may vary 
by sex and family history of dementia, as supported by the literature. Sex and family history 
of dementia have been examined as effect modifiers as they may impact the relationship 
between the exposure, migraines, and the outcome, late-life cognitive health. Family history 
of dementia was used as a proxy for genetic predisposition to dementia. Refer to Figure 3 for 
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Dementia is a major health concern for adults. Migraines are a common form of 
headache disorders that affect millions of people worldwide. Dementia and migraines are 
both neurological disorders that cause significant economic impact and psychological strain 
on society. 
Repeated exposure to migraine attacks causes permanent long-term neurovascular 
damage. Migraines are risk factors for various diseases and disorders, such as hypertension 
and stroke. These disorders are in turn significant risk factors for cognitive impairment and 
dementia. The association between migraines and cognitive health outcomes is biologically 
plausible given the overlap in underlying neuropathophysiology. There is evidence, despite 
conflicting results, that migraines may be related to cognitive impairment. It has been 
observed in one study that migraines are a risk factor for AD (Tyas et al., 2001). Migraines 
sufferers have a higher prevalence of vascular risk factors, suggesting that migraines may be 
a risk factor for VaD. It is clear that the possible relationship between migraines and late-life 






3. Study Rationale 
3.1. Gaps in Research 
Both migraines and dementia are common neurological disorders and represent a global 
health concern, indicating the importance of continued research of these disorders. However, 
the association between migraines and late-life cognitive health outcomes has not been 
thoroughly explored. A relationship between migraines and AD has been observed (Tyas et 
al., 2001), but has yet to be fully examined. Despite evidence that chronic exposure to 
migraine neuropathophysiology can cause permanent neurovascular damage, the link 
between neurological damage caused by migraines in mid-life and late-life cognitive 
function has not been fully explored. 
Modification of the association between migraines and dementia by gender is possible 
given the observed gender differences in rates of migraines and dementia. In addition, 
migraines and epilepsy are linked by overlapping biological mechanisms, which has 
prompted debate over the relationship between epilepsy and dementia (Bigal et al., 2003; 
Hermann et al., 2008; Tellez-Zenteno et al., 2005). It is also possible that genetic factors may 
affect the association between migraines and cognitive health outcomes. As there are many 
unanswered questions regarding migraines and late-life cognitive health outcomes, this 
research area requires further investigation. 
 
3.2. Research Objective 
Using the MSHA dataset, Tyas et al. (2001) investigated various risk factors for AD. 
The results indicated that migraines were one of many significant risk factors for AD. 





migraines and risk for multiple late-life cognitive health outcomes. Since the study by Tyas 
et al. (2001) was not focused on migraines, possible intervening variables such as stroke, 
heart attack or diabetes were not investigated. 
Data from the MSHA will be used to investigate relationships between migraines and 
risk for late-life cognitive health outcomes (dementia, AD, VaD, CIND) taking into 
consideration the possible associated intervening variables. A secondary focus of this study 
is to examine whether the association between migraine and these cognitive health outcomes 
varies by sex, epilepsy, and family history of dementia. 
 
3.3. Research Questions 
Does a history of migraines increase the risk of overall dementia, AD, VaD or CIND? 
a) Do these associations persist after adjusting for potential confounders (age, sex, 
education, and depression)? 
b) Do these associations persist after adjusting for potential intervening variables 
(hypertension, diabetes, stroke, and myocardial infarction)? 








4.1. Literature Search 
 The goal of this literature search was to systematically review the available literature 
relevant to migraines and cognitive impairment. Using various databases, including Medline, 
PsycINFO and Scopus, peer-reviewed articles were identified. 
The key search database utilized was Medline; the interface used for these searches 
was PubMed. Using the MeSH terms “dementia” and “migraine disorders,” 93 articles were 
identified in Medline, including 58 review articles. In order to include articles not 
specifically discussing dementia, the MeSH terms “migraine disorders” and “cognition 
disorders” were used. This search yielded 80 articles, including 23 review articles. All 
articles that focused on the relationship between migraines and cognitive impairment, 
dysfunction, or decline were identified using these searches. As this core search was 
designed to be exhaustive and systematic, all articles were reviewed. 
 To locate relevant articles for migraine background information, broad searches were 
conducted in Medline to identify key review articles and original articles. To identify key 
articles regarding migraine epidemiology and specifically risk factors, the following MeSH 
terms were used: “migraine disorders”, “risk factors”, “depression”, “epilepsy”, 
“hypertension”, “hypercholesterolemia”, “cardiovascular disease”, “cerebrovascular 
disease”, “alcohol drinking” and “smoking”. This broad search yielded 3273 articles, 
including 667 review articles. To identify key articles regarding migraines and 
neuropathophysiology, the following MeSH terms were used: “migraine disorders”, 





50 review articles. The above searches were broad searches to give overall background 
information on migraine disorders. 
 To locate relevant articles for dementia background information, broad searches were 
conducted in Medline to identify key review articles and original articles. To identify key 
articles regarding dementia epidemiology, including AD, VaD and specifically dementia risk 
factors, the following MeSH terms were used: “dementia”, “Alzheimer disease”, “dementia, 
vascular”, “risk factors”, “depression”, “epilepsy”, “cardiovascular disease”, 
“cerebrovascular disease” and “diabetes mellitus”. This all-inclusive search yielded 12425 
articles, including 2514 review articles. To identify key articles regarding MCI or CIND, 
MeSH terms were used in combination with non-MeSH terms ‘mild cognitive impairment’ 
and ‘cognitive impairment no dementia’, as MCI and CIND do not have MeSH terms. The 
MeSH terms included “risk factors” and “epidemiology”. This search yielded 337 articles, 
including 61 review articles. To identify key articles regarding dementia 
neuropathophysiology, the following MeSH terms were used: “dementia”, “inflammation”, 
“pathology”, “physiology”, “cardiovascular disease” and “cerebrovascular disease”, 
“receptors, cholinergic” and “receptors, neurotransmitter”. This search yielded 5315 articles, 
including 1219 review articles. To identify key articles regarding dementia and disability, the 
following MeSH terms were used: “dementia”, “caregivers”, “morbidity” and “mortality”. 
The non-MeSH term “caregiver burden” was also used. This search yielded 6214 articles, 
including 779 review articles. The above searches were broad searches to give overall 





To ensure that all relevant articles were identified, PsycINFO and Scopus were 
utilized in addition to PubMed. The searches performed in these databases confirmed that all 
relevant articles had been identified. 
All searches were limited to English language articles and most were limited to more 
recent articles, within the last 10-15 years. Results from the above searches were manually 
examined for relevance; priority was given to the most recent articles or reviews, as well as 
key reviews in each research area. In addition to using article databases to identify relevant 
articles, article reference lists provided many important articles. Relevant articles were also 
identified by performing citation searches.  
 
4.2. Data Source: Manitoba Study of Health and Aging 
4.2.1. Study Population 
The Canadian Study of Health and Aging (CSHA) is a population-based, longitudinal 
study of aging and dementia in Canada. Participants were adults 65 years of age and older 
and included both community and institutional residents.  
The Manitoba Study of Health and Aging (MSHA) is a parallel study to the CSHA, 
using similar methods for data collection and diagnoses. The MSHA expanded the CSHA 
samples in Manitoba. Unlike the CSHA, the MSHA included rural farming communities, 
villages, towns and small cities. The community sample of the MSHA was derived by 
random sampling from the provincial health plan list. Those excluded were members of the 
military, RCMP, First Nations living on reserves, or residents of a remote, sparsely populated 
region of the province. The study population was stratified by health region and age group 





sufficient numbers of older participants. At baseline (1991/92), 2890 people were contacted 
to be interviewed; 1751 people agreed and were able to participate. Reasons for non-
participation included refusal (n=443), ineligibility (n=480), inability to be contacted 
(n=162) or inability to complete screening (n=54). This resulted in 1751 participants that 
were part of the study sample. At both time points the Modified Mini-Mental State Exam 
(3MS) was used to screen for cognitive impairment. A score of less than 78 on the 3MS 
identified a participant as potentially cognitively impaired. These participants were invited 
for an in-depth clinical examination. At the baseline interview in 1991/92, 1355 participants 
screened not cognitively impaired and comprised the incidence cohort. The Risk Factor 
Questionnaire was left with participants to be sent in by mail: 1039 (76.7%) returned their 
questionnaires. A summary of the MSHA study population and derivation of the analytic 










 data on varia
 of the sample





 to n=961. 
61 
ing study p




tion 4.3.1. for 
 
 of the 






4.2.2. Data Collection 
 The primary purpose of the MSHA was to investigate aging and dementia in 
Manitoba. The focus of the MSHA study at baseline (MSHA-1) was to estimate the 
prevalence of and risk factors for dementia. Also examined were caregiver burden issues, as 
well as patterns of service use for older adults suffering from dementia and their caregivers 
(MSHA Research Group, 1995). The MSHA-2 objectives were to estimate incidence of 
dementia in Manitoba, identify risk factors for dementia and to compare cognitive status 
between MSHA-1 and MSHA-2. The study also continued to focus on caregiver and quality 
of life issues, such as estimating dependence in activities of daily living (ADLs), identifying 
factors that predicted development of frailty and ADL dependence, and examining factors 
associated with institutionalization and community-based service utilization by caregivers 
and community-residing older adults (MSHA-2 Research Group, 1998). At both time points 
in the study, data were collected on a variety of topics using many techniques, including 
interviews, self-reported questionnaires and clinical and psychological examinations. The 
self-report Risk Factor Questionnaire covered important aspects of participants’ health, 
lifestyle and environment that could be risk factors for cognitive impairment. The screening 
interview portion of both the MSHA-1 and MSHA-2 covered key topics including 
sociodemographic characteristics, life satisfaction, psychological well-being, depression, 
health status indicators, chronic illness and ADLs. A screening test for cognitive impairment 
(Modified Mini-Mental State Exam (3MS)) was included and used to determine participation 
in the full clinical evaluation. Following a full clinical evaluation, consensus meetings were 





Using established diagnostic criteria, cognitive status was divided into four 
categories: cognitively intact, possible cognitive impairment, cognitive impairment-no 
dementia and dementia. If a participant scored less than 78 on the 3MS they were considered 
potentially cognitively impaired and were invited to participate in a clinical assessment. This 
assessment then determined if they were cognitively impaired; if so, the type of cognitive 
impairment was identified. The dementia categories included AD, VaD, other specific 
dementia and unclassifiable dementia. Unclassifiable dementia included those who could not 
be diagnosed with another specific type of dementia (n=3; 2.1%). Overall dementia was 
diagnosed using the DSM-IV criteria (Hebert et al, 2000; DSM-IV, 1994). The diagnostic 
categories of probable AD and possible AD were assigned according to the NINCDS-
ADRDA criteria (McKhann et al., 1984, Tyas et al., 2001). VaD was diagnosed using the 
DSM-III criteria at time 1 and NINDS-AIREN criteria at time 2 (Hebert et al, 2000; Roman 
et al., 1993). Diagnoses of CIND were based on the exclusion of dementia, despite the 
presence of impairment identified through clinical examination and neuropsychological tests 
(Graham et al., 1997). 
 
4.3. Current Thesis Project 
4.3.1. Sample Population 
 The analyses for the thesis project are based on the incidence cohort of 1039 
individuals who screened cognitively intact at the time 1 interview of the MSHA. The study 
used data from individuals who completed the MSHA-Risk Factor Questionnaire, were 





(n=716). See Figure 3 for a summary of the MSHA study population and derivation of the 
analytic sample. 
All variables were assessed for missing data. Specifically, 23 individuals had missing 
data on the exposure variable, history of migraines. The variable educational level had 19 
individuals with missing or incomplete data (see Appendix B for further details). Twenty-
three individuals had missing data on the variable depression. Twenty-five individuals had 
missing data on myocardial infarction, whereas 37 individuals had missing data on “other 
heart condition”. Twenty individuals had missing data on stroke and diabetes. Finally, 26 
individuals had missing data on hypertension.  
Due to the hierarchical method of sample reduction, missing data for variables were 
often accounted for in previous reduction steps, as missing data for each variable were not 
mutually exclusive. Missing data on key MSHA-1 variables reduced the analytic sample for 
this study from 1039 to 961, as follows. Missing data on migraine history reduced the sample 
size from 1039 to 1016. Missing data on the educational level further reduced the sample to 
997. Missing data on depression reduced the sample to 992. Exclusion of participants 
missing data on myocardial infarction reduced the sample from 992 to 984. Missing data for 
the variable “other heart condition” further reduced the sample from 984 to 971. Missing 
data on stroke reduced the sample from 971 to 969 and diabetes further reduced the sample 
from 969 to 961. The missing hypertension data were accounted for in previous steps. 
Excluding those unable to complete the screening interview at MSHA-2 (moved 
n=15; refused n=31; sick n=8; died n=165) reduced the sample size to 742. The final analytic 
sample was determined by restricting to those with complete data on their cognitive status at 





undergo clinical assessment as well as those who screened below the cut-point and were 
referred to and completed the clinical assessment (n=716). Twenty-six participants were 
missing cognitive outcome data, as they did not complete the MSHA-2 Clinical Examination 
(no contact n=1; refused n=15; sick n=3; died n=7). 
In the final analytic sample, among participants suffering from migraines (n=74), 
duration of migraine disorder was available on a subset of the sample (n=36). Analyses have 
been done on this subset where sample sizes permit.  
 
4.3.2. Variable Selection 
 The study primarily used variables from the MSHA-1 Risk Factor Questionnaire. 
However, a small number of variables from the MSHA-1 and the MSHA-2 Screening 
Interviews were also utilized. The exposure variables (history of migraines and duration of 
migraine disorder) are from the MSHA-1 Risk Factor Questionnaire. The migraine variables 
were used to explore the possible association with cognitive outcomes, using the final 
diagnosis from the MSHA-2 Screening Interviews and clinical examinations. Cognitive 
status (i.e., final diagnosis) at MSHA-1 was used to identify a cognitively intact sample at 
baseline and to determine cognitive outcomes at MSHA-2. The specific cognitive outcomes 
used as the outcome variables include overall dementia, AD, VaD and CIND. 
The variables from the MSHA-1 Screening Interview included the possible 
confounders age, sex, and education. The variables from the MSHA-1 Risk Factor 
Questionnaire included potential intervening variables (hypertension, diabetes, stroke, 
myocardial infarction and other heart conditions), family history of dementia, depression and 





therefore does not include silent or undiagnosed strokes. Epilepsy was unable to be examined 
as a confounding variable as only one study participant in the analytic sample suffered from 
this disorder. For a full list of variables and sources see Appendix C.  
 
4.4. Data Access Request Protocol 
 To gain access to the MSHA dataset, a formal request was sent to the MSHA 
Research Centre at the University of Manitoba’s Centre on Aging. The request included a 
brief background of the proposed research project, proposed data analysis strategy, estimated 
timeline for completion and a table of all variables of interest. Data access approval was 
granted on November 24th, 2010. A copy of the approved data access request is provided in 
Appendix D. 
 
4.5. Ethics Approval 
  The MSHA and MSHA-2 received ethics approval from the Faculty Committee on 
the Use of Human Subjects in Research at the University of Manitoba. This thesis study 
received ethics approval on November 8th, 2010 from the University of Waterloo Office of 







5. Data Analysis 
 All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, North 
Carolina). General statistical methods and specific analyses are outlined in the following 
sections. 
 
5.1. Descriptive Analyses 
Univariate and bivariate analyses have been conducted to provide an overall sample 
description. These descriptive analyses have been conducted for all variables, including the 
general sample characteristics, intervening and confounding variables, as well as exposure 
variables and outcomes. The characteristics of the full and analytic samples have been 
compared to assess nonresponse bias. The association between exposure variables and 
various outcomes has been examined as outlined in the analytic plan (see Table 3). For 
bivariate analyses, Pearson chi-square values have been used to measure the associations 
between categorical variables, with Fisher’s exact tests used as necessary. The strength of the 
associations has been assessed using odds ratios (OR) and 95% confidence intervals (CI). T-
tests with unequal variance assumption have been used to measure the associations between 







Table 3: Analytic plan for migraine history and dementia including statistical method 





Statistical method: Logistic regression 
Outcome variable: Dementia  
Exposure variable: Migraine history (Y/N) 
Confounding variables: --- 




Statistical method: Logistic regression 
Outcome variable: Dementia  
Exposure variable: Migraine history (Y/N) 
Confounding variables: Age, sex, education, epilepsy1 and 
depression 






Statistical method: Logistic regression 
Outcome variable: Dementia  
Exposure variable: Migraine history (Y/N) 
Confounding variables: Age, sex, education, epilepsy1 and 
depression  
Intervening variables: Hypertension, diabetes, stroke, myocardial 
infarction and other heart condition 
Dementia: 
Final 
Statistical method: Logistic regression 
Outcome variable: Dementia 
Exposure variable: Migraine history (Y/N) 
Confounding variables: Significant variables 
Intervening variables: Significant variables 
*reflects the set of models to assess the association between migraines and overall dementia. This set of models 
has been repeated for each remaining outcome: Alzheimer’s disease, vascular dementia and cognitive 
impairment-no dementia; as well as repeated for all outcomes for the other measure of migraine exposure 
(duration). 







5.2. Multivariate Modeling 
 In order to meet the stated research objective, a set of research questions were 
developed. The plan of analysis for each question is described in Table 3 and Table 4 below 
for the exposure variable “history of migraines.” The analytic strategies shown below have 
also been used for the secondary exposure variable, duration of migraine disorder. The 
variables involved are listed for each analytic strategy. The model name indicates the 
outcome variables that are being referred to (dementia, AD, VaD, CIND). The model name 
also indicates which subquestion of each research question is being addressed (i.e., which 
variables are included).  
The influence of exposure, confounding and intervening variables on the outcomes of 
interest was assessed using multiple logistic regression procedures. Although backward 
elimination was the preferred method of variable selection for the logistic regression models 
(Tyas, Koval & Pederson, 2000), sample sizes were insufficient to support backward 
elimination and thus stepwise selection methods for variable selection were used. The 
significance (α) levels used for the stepwise selection regression models were 0.15 for main 
effects and 0.05 for interactions. Significance was defined as a p-value less than 0.05. Results 
with p-values less than 0.10, but greater or equal to 0.05 were considered marginally 
significant. The logistic regression models were adjusted for the potential confounding 
variables age, sex, education, and depression. All variables were assessed for first-order 
interactions with the exposure variable history of migraines in the dementia and AD models: 
no significant interactions were observed. In addition, given the a priori hypothesized effect 
modification by sex and family history of dementia, the association between migraines and 





investigated regardless of the significance of the relevant interaction terms. Hosmer-
Lemeshow goodness of fit (H-L GOF) tests were performed on each model. Models were 
rejected if they had a p-value of <.05 for the H-L GOF. Additional model diagnostics to 
assess model fit, including assessment of influential outliers and tests of collinearity, were 
performed on all final models. Assessment of influential outliers was achieved by analysing 
DFBETA, C and CBAR results from SAS outputs for residual diagnostics. If participants had 
DFBETA, C or CBAR values exceeding the cut-point of +/-1.96, which corresponds to a 
significance level of 0.05, they would be deleted and the model re-run. Collinearity between 
variables was also assessed using SAS. The standard recommended by Kleinbaum et al. 
(1988) indicates the presence of multicollinearity between variables when two or more 
variance proportions greater than 0.90 are associated with condition indices greater than 30. 
For a more in-depth description of the multivariate modeling techniques that were used, see 






Table 4: Analytic plan for migraine history and dementia including statistical method 





Statistical method: Logistic regression 
Outcome variable: Dementia  
Exposure variable: Migraine history (Y/N) 
Confounding variables: --- 
Intervening variables: --- 





Statistical method: Logistic regression 
Outcome variable: Dementia  
Exposure variable: Migraine history (Y/N) 
Confounding variables: Age, sex, education, epilepsy2 and 
depression 
Intervening variables: --- 







Statistical method: Logistic regression 
Outcome variable: Dementia  
Exposure variable: Migraine history (Y/N) 
Confounding variables: Age, sex, education, epilepsy2 and 
depression  
Intervening variables: Hypertension, diabetes, stroke, myocardial 
infarction and other heart condition 
Effect modifiers: Sex, and family history of dementia3 
1Due to sample sizes stratification by family history of dementia was only possible when performed on the 
unadjusted dementia model. Stratification by sex was not able to be performed for any model. 
2Epilepsy was unable to be used as a confounding variable as only one participant suffered from this disorder 










 Age and educational level were recoded to avoid small cell sizes. Age was recoded 
from a continuous variable into three categories: 65-74 years of age, 75-84 years of age and 
85 years of age or older. Educational level was originally classified into 12 categories: No 
formal school; Some primary school; Finished primary school; Some high school; 
Completed high school; Some college; Completed college; Some university; Bachelor’s 
degree; Master’s degree; PhD; and Other. These categories were recoded to four categories:  
Did not complete primary school; Completed primary school; Completed high school; and 
Completed college/university (Bachelor’s degree; Master’s degree; PhD). In order to assess 
the appropriateness of the recoded educational level, the original educational level with 12 
categories was compared to the recoded educational level with 4 categories. Although the 4-
level classification of education differed significantly between the exclusion sample and the 
remainder sample, as well as the analytic sample and the remainder of the exclusion sample, 
this pattern did not differ from that of the original 12-level classification (see Appendix B). 
 
5.2.2. Age of Onset 
 
This thesis project explored age of onset of migraine disorder as a possible exposure 
variable using the length of time that participants suffered from migraines and their age when 
they reported the duration of their migraines. Migraine duration data, however, were only 
reported by a subset (n=36) of those with a history of migraines (n=74). Migraine duration 
ranged from 0.5 to 70 years among those who had a history of migraines. Of the thirty-six 
individuals included in the analytic sample with migraine duration data, the mean migraine 





longer they would have suffered from migraines. However, a dose-dependent relationship 
was not observed between age and migraine duration: a negative correlation (correlation 
coefficient=-0.14, p=0.42) was observed between migraine duration and age. In addition, 
many of those experiencing the longest duration of migraine disorder were in the youngest 
two age groups (65-74 years and 75-84 years). Only one participant with migraine duration 
data was in the oldest age group (85+ years) and reported experiencing migraines for only 10 
years. These results raised concerns in interpretation and, in addition to the limited sample 







6.1. Sample Description 
 The characteristics of the analytic sample (n=716) are presented in Table 5. The study 
sample characteristics (n=1039) can be found in Appendix F. The derivation of the analytic 
sample from the study sample is described in Section 4.3.1 (Figure 2).  
The sample excluding all missing data on exposure, intervening and confounding 
variables (n=961 – exclusion sample) was compared to the remainder of the study sample 
(n=1039 - n=961, i.e., n=78) to assess response bias and the representativeness of the sample. 
Response bias comparison results for the exclusion sample (n=961) compared to the 
remainder of the study sample (n=78) are shown in Appendix G: Table 1. All outcomes and 
confounding and intervening variables, except educational level, did not differ significantly 
between the exclusion sample and the remainder of the study sample. Educational level 
differed significantly between the exclusion sample and the remainder of the study sample. 
This was due to the exclusion of the educational level “Other” from the exclusion sample 
(see Appendix B: Coding of Education: Removal of “Other” Category from the Educational 
Level Variable). 
The final analytic sample (n=716) was compared to the remainder of the exclusion 
sample (n=961 - n=716, i.e., n=245) to assess response bias and the representativeness of the 
sample. Response bias assessment of the analytic sample (n=716) compared to the remainder 
of the exclusion sample (n=245) is presented in Appendix G: Table 2. When comparing the 
analytic sample to the remainder of the exclusion sample, dementia, AD, and CIND were 
found to differ significantly between the two samples. The above late-life cognitive health 





diagnosed with dementia, 4.8% were diagnosed with AD, and 5.2% were diagnosed with 
CIND. Within the remainder of the exclusion sample, there were no cases of CIND or any 
type of dementia. 
Among the confounding and intervening variables, age, education in years and level, 
as well as myocardial infarction and stroke were found to differ significantly between the 
two samples. The average age of participants in the analytic sample was 75.9 (SD=6.1) years 
compared to an average of 78.5 (SD=7.4) years for those in the remainder of the exclusion 
sample. Within the analytic sample, 42.2% were 65 to 74 years of age compared to 33.9% of 
the remainder of the exclusion sample. Of participants in the analytic sample, 48.3% were 
between the ages of 75 and 84 years compared to 40.8% of the remainder of the exclusion 
sample. Finally, 9.5% of the analytic sample was over the age of 85 compared to 25.3% of 
the remainder of the exclusion sample. Participants in the analytic sample achieved an 
average of 10.4 (SD=3.1) years of education, compared to 9.7 (SD=3.2) years in the 
remainder of the exclusion sample. Educational level differed significantly between the two 
samples. Those who completed the final cognitive assessment were more likely to have 
completed college or university, compared to those who did not make it to the final cognitive 
assessment. 
Within the analytic sample, 5.2% of participants suffered from a stroke compared to 
9.8% of participants in the remainder of the exclusion sample. A greater number of 
participants reported myocardial infarction: 7.8% within the analytic sample and 15.1% in 






































































































































































































6.2. Bivariate Results 
 
Bivariate analyses were performed between cognitive outcomes and all other 
variables within the analytic sample (n=716). Results are summarized in Table 6, with odds 
ratios presented in Table 7. 
Within the analytic sample, 13.9% of participants diagnosed with dementia also had 
migraines; this relationship between dementia and migraines is marginally significant. Of 
participants diagnosed with AD, 11.4% also had migraines; this relationship between AD and 
migraines is statistically significant. The relationship between CIND and migraine duration 
was also marginally significant, with 5.3% suffering from CIND. In addition, the odds of 
developing overall dementia or AD were significantly increased in those with a history of 
migraines. Migraine sufferers had 2.23 times greater odds of developing overall dementia 
and 2.81 times greater odds of developing AD. For additional bivariate odds ratio results, see 
Table 8. 
The mean age of the participants varied with different cognitive outcomes: 81.5 years 
for participants diagnosed with dementia (SD=5.3) and AD (SD=5.6), 81.7 (SD=5.5) years 
for those with VaD, 80.3 (SD=7.3) years for those with CIND, and 75.1 (SD=5.7) years for 
those who were cognitively intact. Each cognitive outcome (AD, VaD, CIND) was 
significantly associated with age (categorized into groups: 65-74 years, 75-84 years and 85 
years of age or older). For the participants diagnosed with dementia, AD, and CIND, the 
relationship between each cognitive outcome and age was statistically significant, whereas 
the relationship between VaD and age was marginally significant. 
The relationship of dementia, AD, VaD, and CIND with years of education was 





education was attained: 8.8 years for those with AD (SD=3.4) and VaD (SD=2.8), and 8.7 
(SD=2.7) years for those with CIND. The mean number of years of education attained for 
those who were cognitively intact was 10.6 (SD=3.0) years. Among those diagnosed with 
dementia, AD and CIND, the relationship between each cognitive outcome (dementia, AD, 
CIND) and educational level was found to be statistically significant. In contrast, educational 
level was not significantly associated with VaD. 
Various health conditions, including depression, stroke and other heart conditions, 
were also found to be significantly associated with dementia, including both VaD and CIND. 
None of these health conditions were significantly associated with AD. Depression was 
found to be significantly associated with CIND. Among the participants diagnosed with 
CIND, 21.6% also had depression, whereas only 8.6% of participants without CIND were 
also diagnosed with depression. The relationship between dementia and stroke was 
statistically significant. Among participants diagnosed with dementia, 13.7% had also had a 
stroke, compared to only 4.3% in those without dementia. In addition, VaD was significantly 
associated with stroke, as well as other heart conditions. Of the participants diagnosed with 
VaD, 33.3% had also had a stroke and 41.7% also had another heart condition, compared to 
4.3% and 16.6% respectively in those without VaD. 
Bivariate analyses were also performed between the exposure variables, history of 
migraines and duration of migraine disorder, and all variables within the analytic sample 
(n=716). All statistically significant results are discussed in this section; all migraine 
bivariate results are presented in Appendix H. 
For participants suffering from migraines, 17.6% were male and 82.4% female. For 





migraines were 2.83 times more likely to suffer from depression. In addition, 10.8% also 
reported having had a stroke and 14.9% reported diabetes. Those with a history of migraines 
were 2.94 times more likely to suffer from diabetes and 2.56 times more likely to have a 
stroke. Age was marginally significantly associated with migraine (see Appendix H: Table 1 
for more results).  
Unadjusted models for each outcome were performed for the exposure variable, 
duration of migraine disorder. However, the results were not statistically significant (see 
Appendix H: Table 2). In addition, there is the potential for confounding in the duration of 
migraine disorder models, as we were unable to adjust the models; interactions were also 
unable to be assessed. A positive correlation or protective effect was observed between 
duration of migraine disorder and age, indicating that older individuals were more likely to 
have a shorter duration of migraine disorder. However, this relationship was not statistically 
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Table 7: Crude odds ratios for each late-life cognitive health outcome by exposure, confounding and intervening variables in the 
Manitoba Study of Health and Aging (n=716) 
 
 Dementia AD1 VaD2 CIND3
     
Exposure Variables     
History of migraines 2.23 (1.06-4.66) 2.81 (1.22-6.47) 1.83 (0.39-8.52) 0.48 (0.11-2.04) 
Confounding Variables         
Sex 0.80 (0.44-1.46) 0.76 (0.37-1.59) 0.80 (0.24-2.68) 0.99 (0.50-1.95) 
Depression 1.42 (0.58-3.47) 1.03 (0.30-3.48) 3.54 (0.93-13.48) 2.85 (1.25-6.50) 
Family history of dementia 0.63 (0.19-2.08) 0.66 (0.15-2.84) 0.78 (0.10-6.13) 1.30 (0.44-3.85) 
Intervening Variables         
Hypertension 1.51 (0.84-2.70) 1.18 (0.57-2.42) 2.16 (0.69-6.77) 1.42 (0.72-2.80) 
Diabetes 1.60 (0.6-4.24) 1.96 (0.66-5.84)     --*  0.81 (0.19-3.46) 
Stroke 3.54 (1.46-8.59) 1.39 (0.32-6.11) 11.13 (3.15-39.26) 1.67 (0.49-5.73) 
Myocardial infarction 1.26 (0.48-3.31) 1.12 (0.33-3.79) 1.05 (0.13-8.31) 0.32 (0.04-2.34) 
Other heart condition 1.55 (0.79-3.06) 1.08 (0.44-2.67) 3.60 (1.12-11.56) 1.56 (0.72-3.39) 
*Unable to calculate odds ratio as no participants suffered from both vascular dementia and diabetes 






6.3. Association of Dementia with Migraine History 
6.3.1. Unadjusted Dementia Model 
In the unadjusted analyses of history of migraine by dementia, the odds of dementia 
were 2.23 (95% CI: 1.06-4.66) times higher in those with a history of migraines than in those 
without a history of migraines (Table 8).  
 
6.3.2. Dementia Model with Confounding Variables 
The dementia model with confounding variables allowed confounding variables that 
met the required level of significance to enter the model. The odds of dementia were 3.28 
(95% CI: 1.41-7.21) times higher in those with a history of migraines than in those without a 
history of migraines, in the presence of the significant confounders age and education. The 
odds of dementia in those with a history of migraines increased when confounding variables 
were added to the model (OR=3.28) compared to the unadjusted dementia model (OR=2.23). 
Increasing age was significantly related to the odds of developing dementia. Higher 
educational level decreased the odds of developing dementia. For more detailed results on all 
variables examined, see Table 8.  
 
6.3.3. Dementia Model with Confounding and Intervening Variables 
The odds of dementia were 2.97 (95% CI: 1.25-6.61) times higher in those with a 
history of migraines than in those without a history of migraines, in the presence of 
significant confounding and intervening variables. The odds of dementia in those with a 
history of migraines decreased when significant confounding (age, educational level) and 





with confounding variables only (OR=3.28). In spite of stroke meeting the criteria to enter 
the model, it was not an independent statistically significant predictor of dementia. However, 
the presence of stroke affected the strength of the association between migraines and 
dementia. Both age and educational level were significant predictors of dementia. Increasing 
age was significantly related to increased odds of developing dementia. Higher educational 
level decreased the odds of developing dementia. For more detailed results for all variables 
examined, see Table 8.  
All dementia models met statistical specifications for model fit and had no influential 
outliers or multicollinearity issues. 
 
6.3.4. Dementia Model Stratified by Family History of Dementia 
 Due to small sample sizes, stratification by family history of dementia was limited to 
a dementia model without adjustment for covariates. When stratified by family history of 
dementia, migraines were not a statistically significant predictor for the development of 
dementia in those with (OR=3.64; 95% CI: 0.29-45.60) or without a family history of 
dementia (OR=1.43; 95% CI: 0.58-3.57). The interaction term, migraine by family history of 
dementia, was also not statistically significant. 
 Stratification of each model by sex was not possible as no male participants suffered 
from migraines as well as dementia and only one male participant suffered from migraines as 






Table 8: Association of migraine history with dementia in the Manitoba Study of 
Health and Aging (n=716)  
 
 Dementia 







  OR (95% CI)  
Exposure    
Migraine history 2.23 (1.06-4.66) 3.28 (1.41-7.21) 2.97 (1.25-6.61) 
Confounding Variables    
Age group:    
65-74 years 1 1.0 1.0 
75-84 years  4.36 (1.89-11.90) 4.21 (1.82-11.58) 
85+ years  21.94 (8.24-66.06) 20.60 (7.73-62.06) 
Sex (male)  2- - 
Educational level:    
Did not complete primary 
school 
 1.0 1.0 
Completed primary school  0.41 (0.18-1.01) 0.41 (0.17-1.01) 
Completed high school  0.32 (0.12-0.87) 0.32 (0.12-0.86) 
Completed college/university  0.30 (0.10-0.88) 0.32 (0.10-0.94) 
Depression   - 
Intervening Variables    
Hypertension   - 
Diabetes   - 
Stroke   2.52 (0.90-6.42) 
Heart attack   - 
Other heart condition   - 
1 Crossed out cells indicate variables that were not eligible to be included in that model. 
2 A dash (-) in a cell indicates variables that did not meet the required level of significance to 






6.4. Association of Alzheimer’s Disease with Migraine History 
6.4.1. Unadjusted Alzheimer’s Disease Model  
In the unadjusted analyses of history of migraine by AD the odds of AD were 2.81 
(95% CI: 1.22-6.47) times higher in those with a history of migraines than in those without a 
history of migraines (Table 9). 
 
6.4.2. Alzheimer’s Disease Model with Confounding Variables 
The AD model with confounding variables allowed confounding variables that met 
the required level of significance to enter the model. The odds of AD were 4.22 (95% CI: 
1.59-10.42) times higher in those with a history of migraines than in those without a history 
of migraines, in the presence of age and educational level. The odds of AD in those with a 
history of migraines increased when confounding variables were added to the model 
(OR=4.22) compared to the unadjusted AD model (OR=2.81). Increasing age was 
significantly related to increased odds of developing AD. Higher educational level decreased 
the odds of developing AD. For more detailed results on all variables examined, see Table 9.  
 
6.4.3. Alzheimer’s Disease Model with Confounding and Intervening Variables 
The odds of AD were 4.22 (95% CI: 1.59-10.42) times higher in those with a history 
of migraines than in those without a history of migraines, in the presence of significant 
confounding and intervening variables. The odds of AD in those with a history of migraines 
did not change when confounding and intervening variables were added to the model, 
compared to the AD model with confounding variables only because there were no 





confounding as well as intervening variables, only the confounders age and educational level 
met the required level of significance to enter the model. For more detailed results on all 
variables examined, see Table 9.  
All AD models met statistical specifications for model fit and had no influential 






Table 9: Association of migraine history with Alzheimer’s disease in the Manitoba 
Study of Health and Aging (n=716)  
 
 Alzheimer’s disease 







  OR (95% CI)  
Exposure    
Migraine history 2.81 (1.22-6.47) 4.22 (1.59-10.42) 4.22 (1.59-10.42) 
Confounding Variables    
Age group:    
65-74 years 1 1.0 1.0 
75-84 years  4.16 (1.51-14.67) 4.16 (1.51-14.67) 
85+ years  23.03 (7.12-90.12) 23.03 (7.12-90.12) 
Sex (male)  2- - 
Educational level:    
Did not complete primary 
school 
 1.0 1.0 
Completed primary school  0.35 (0.14-0.99) 0.35 (0.14-0.99) 
Completed high school  0.18 (0.05-0.61) 0.18 (0.05-0.61) 
Completed college/university  0.32 (0.09-1.05) 0.32 (0.09-1.11) 
Depression   - 
Intervening Variables    
Hypertension   - 
Diabetes   - 
Stroke   - 
Heart attack   - 
Other heart condition   - 
1 Crossed out cells indicate variables that were not included in that model. 
2 A dash (-) in a cell indicates variables that did meet the required level of significance to 








6.5. Association of Vascular Dementia with Migraine History 
6.5.1. Unadjusted Vascular Dementia Model  
In the unadjusted analyses of history of migraine by VaD the odds of VaD were 1.83 
(95% CI: 0.39-8.52) times higher in those with a history of migraines than in those without a 
history of migraines (Table 10). However, this result was not statistically significant. Due to 
small sample sizes, interactions could not be assessed in the VaD models.  
 
6.5.2. Vascular Dementia Model with Confounding Variables 
The VaD model with confounding variables allowed confounding variables that met 
the required level of significance to enter the model. The odds of VaD were 2.21 (95% CI: 
0.32-9.77) times higher in those with a history of migraines than in those without a history of 
migraines, in the presence of significant confounders age and depression. The association of 
migraine history with VaD was not statistically significant. Depression met criteria to be 
entered into the model, but was not an independent significant predictor of VaD. However, 
the odds of VaD in those with a history of migraines increased in the adjusted model 
(OR=2.21) compared to the unadjusted VaD model (OR=1.83). Increasing age was 
significantly related to the odds of developing VaD. For more detailed results on all variables 
examined, see Table 10.  
 
6.5.3. Vascular Dementia Model with Confounding and Intervening Variables 
The odds of VaD were 1.52 (95% CI: 0.20-7.23) times higher in those with a history 
of migraines than in those without a history of migraines, in the presence of significant 





Despite allowing all potential confounding as well as intervening variables to be included in 
the model, only age, depression and stroke met the required level of significance to enter the 
model. When the intervening variables were included in the model the odds ratio between 
migraines and VaD dropped from 2.21 to 1.52. Increasing age was significantly related to 
increased odds of developing VaD. Additionally, those who suffered from stroke were 
significantly more likely to develop VaD. For more detailed results on all variables 
examined, see Table 10.  
All VaD models met statistical specifications for model fit and had no influential 






Table 10: Association of migraine history with vascular dementia in the Manitoba 
Study of Health and Aging (n=716)  
 
 Vascular dementia 







  OR (95% CI)  
Exposure    
Migraine history 1.83 (0.39-8.52) 2.21 (0.32-9.77) 1.52 (0.20-7.23) 
Confounding Variables    
Age group:    
65-74 years 1 1.0 1.0 
75-84 years  3.04 (0.69-21.0) 2.87 (0.64-20.09) 
85+ years  17.38 (3.16-133.44) 14.28 (2.46-112.64) 
Sex (male)  2- - 
Educational level:    
Did not complete primary 
school 
 - - 
Completed primary school  - - 
Completed high school  - - 
Completed college/university  - - 
Depression  3.51 (0.73-13.03) 2.95 (0.57-11.61) 
Intervening Variables    
Hypertension   - 
Diabetes   - 
Stroke   7.90 (1.82-29.71) 
Heart attack   - 
Other heart condition   - 
1 Crossed out cells indicate variables that were not included in that model. 
2 A dash (-) in a cell indicates variables that did meet the required level of significance to 








6.6. Association of CIND with Migraine History 
6.6.1. Unadjusted CIND Model  
In the unadjusted bivariate analyses of history of migraine by CIND the odds of 
CIND were 0.52 (95% CI: 0.12-2.22) times higher in those with a history of migraines than 
in those without a history of migraines (Table 11). However, this result was not statistically 
significant. Due to small sample sizes, interactions could not be assessed in the CIND 
models. 
 
6.6.2. CIND Model with Confounding Variables 
The CIND model with confounding variables allowed confounding variables that met 
the required level of significance to enter the model. The odds of CIND were 0.70 (95% CI: 
0.11-2.57) times higher in those with a history of migraines than in those without a history of 
migraines, in the presence of age, educational level and depression. When the confounding 
variables were included in the model, the association between migraines and CIND 
weakened (crude OR=0.52 vs. adjusted OR=0.70). However, the association between 
migraine history and CIND was not statistically significant. Increasing age was significantly 
related to increased odds of developing CIND. Higher educational level decreased the odds 
of developing CIND. In addition, those who reported depression were significantly more 
likely to develop CIND. For more detailed results on all variables examined, see Table 11.  
 
6.6.3. CIND Model with Confounding and Intervening Variables 
The CIND model with confounding and intervening variables allowed confounding 





odds of CIND were 0.70 (95% CI: 0.11-2.57) times higher in those with a history of 
migraines than in those without a history of migraines, in the presence of age, educational 
level and depression. The association between migraine history and CIND was not 
statistically significant and did not differ from the model including only potential 
confounders, because there were no significant intervening variables. For more detailed 
results on all variables examined, see Table 11.  
All CIND models met statistical specifications for model fit and had no influential 






Table 11: Association of migraine history with cognitive impairment-no dementia 
(CIND) in the Manitoba Study of Health and Aging (n=716)  
 
 Cognitive impairment-no dementia 







  OR (95% CI)  
Exposure    
Migraine history 0.52 (0.12-2.22) 0.70 (0.11-2.57) 0.70 (0.11-2.57) 
Confounding Variables    
Age group:    
65-74 years 1 1.0 1.0 
75-84 years  1.28 (0.55-3.07) 1.28 (0.55-3.07) 
85+ years  10.01 (3.92-26.50) 10.01 (3.92-26.50) 
Sex (male)  2- - 
Educational level:    
Did not complete primary 
school 
 1.0 1.0 
Completed primary school  0.47 (0.19-1.26) 0.47 (0.19-1.26) 
Completed high school  0.27 (0.08-0.84) 0.27 (0.08-0.84) 
Completed college/university  0.06 (0.003-0.37) 0.06 (0.003-0.37) 
Depression  3.52 (1.36-8.45) 3.52 (1.36-8.45) 
Intervening Variables    
Hypertension   - 
Diabetes   - 
Stroke   - 
Heart attack   - 
Other heart condition   - 
1 Crossed out cells indicate variables that were not included in that model. 
2 A dash (-) in a cell indicates variables that did meet the required level of significance to 








 Healthy aging, including cognitive health, has become a significant focus for 
researchers as the Canadian population ages. An important part of understanding late-life 
cognitive health is understanding late-life cognitive impairments and their mid-life risk 
factors. The possible relationship between migraines and late-life cognitive health outcomes 
was highlighted by the literature review, which also identified gaps in the research. This 
thesis project developed hypotheses based on results and gaps in the research (Breteler et al., 
1991; Tyas et al. 2001). The primary hypothesis driven by the literature is the possibility that 
migraines are a mid-life risk factor for developing late-life cognitive impairment. In addition, 
the possible intervening relationship of vascular risk factors on the relationship between 
migraines and late-life cognitive health outcomes, as well as modification by sex and family 
history of dementia, were also questions directed by the literature review.  
 
7.1. Overall Findings 
The incidence rates of overall dementia and AD found in this study, 7.5% and 5.1% 
respectively, are similar to what have been presented in the literature (Alzheimer’s 
Association, 2009; Alzheimer Society, 2010). The incidence of VaD observed in this study, 
1.9%, is also similar to what has been seen in the literature (see review by Jellinger, 2008). 
The incidence of CIND observed in this study was 5.6%. As this result represents incident 
cases of CIND, it is lower than prevalence rates previously reported in the literature (see 
reviews by Petersen et al., 2009; Tedeschi et al., 2008). However, incidence rates are known 






This thesis project has indicated that migraines are a significant risk factor for both 
overall dementia and AD. However, the relationship between migraines and overall dementia 
appears to be mostly driven by the significant relationship between migraines and AD. 
Despite not observing a significant relationship between a history of migraines and VaD, 
stroke was found to be a significant intervening variable in the pathway between migraines 
and VaD. A non-significant relationship was observed between migraines and CIND, with 
depression as an independently significant variable along this pathway. 
Although the relationship between migraines and overall dementia appears to be 
primarily driven by the significant relationship between migraines and AD, the association 
between migraines, VaD and stroke also plays a role. Despite stroke not being an 
independent statistically significant predictor of dementia, it did meet the criteria to enter the 
model. This is most likely due to the strong association between stroke and VaD, as no 
vascular risk factors were found to be significantly related to AD. 
Despite the vascular mechanisms involved in migraine biology, migraines were not a 
significant risk factor for VaD. Stroke was a significant risk factor for VaD, which has been 
previously demonstrated in the literature (Hachinski et al., 1975; see reviews by Patterson et 
al., 2007). Furthermore, migraines are a significant risk factor for stroke (Bigal et al., 2010; 
see reviews by Bigal et al., 2009; Scher, Bigal & Lipton, 2005). This is supported by the 
significant bivariate association between migraines and stroke in this thesis. When the 
intervening variables (including stroke) were included in the VaD model, the strength of the 
association between migraines and VaD decreased and stroke remained a significant 
predictor. The lack of a significant relationship between VaD and migraines may be driven 





by the observation that migraines were not a significant risk factor for VaD before or after 
the addition of stroke as an intervening variable. However, this type of relationship may 
indicate that the association between migraines and VaD is affected by presence of stroke as 
an intervening variable. The literature and results suggest that any relationship between 
migraines and VaD is dependent on the occurrence of stroke. These results demonstrate an 
area of research to be investigated further in the future. 
Results from this thesis project suggest that migraines are a significant risk factor for 
the development of AD. This result supports what has been previously reported by Tyas et al. 
(2001) in the same data set. However, this thesis project’s results are not supported by 
Breteler et al. (1991), who found an inverse relationship between AD risk and migraines 
(RR=0.7, 95% CI:0.5-1.0). However, one study included in that meta-analysis reported a 
non-significant higher risk of AD for those with headaches (French et al., 1985). In addition, 
the studies included in the meta-analysis by Breteler et al. (1991) utilized a case-control 
study design, compared to the longitudinal study design of the MSHA used by Tyas et al. 
(2001) as well as this study. A longitudinal study design is more appropriate when 
attempting to assess a temporal sequence between migraines and late-life cognitive health 
outcomes. Furthermore, the studies included in the Breteler et al. (1991) meta-analysis did 
not always differentiate between severe headaches or migraines. Moreover, headaches or 
migraines were not the primary risk factor being investigated, but rather just one of many 
health and environmental risk factors being examined by the studies. These differences 
suggest that different samples may yield different results depending on study design, and the 
criteria and definitions used for diagnoses, especially in an emerging field of research, as 





for headaches, migraines or cognitive impairments may play an important role in 
determining if there is a significant relationship between migraines and AD. The significant 
relationship, observed in this study, between migraines and AD may be the result of various 
biological mechanisms. Previous studies have observed relationships between vascular risk 
factors and AD (Alonso et al., 2009; Fillit et al., 2008; Hebert et al., 2000; Whitmer et al., 
2005), as well as vascular risk factors and migraines (Bigal et al., 2009; see reviews by Bigal 
et al., 2010; Scher et al., 2005). Despite these results in the literature, it appears that the 
relationship between migraines and AD cannot be explained in this study by vascular 
dysfunction in the brain, as there was no significant association between vascular variables 
and the relationship between migraines and AD. 
A possible alternative explanation for the relationship between migraines and AD 
may be the specific location of damage in the brain due to migraine neuropathophysiology. A 
variety of cognitive domains can be affected by cognitive impairment; the domains affected 
are specific to dementia type. The different cognitive domains affected by migraine 
neuropathophysiology may indicate specific relationships to dementia types. It is difficult to 
determine the cognitive domains affected by migraines, as migraine research often tests a 
wide variety of cognitive domains and yields a similar wide variety of results (See Table 3). 
However, the relationship between migraines and specific cognitive domains may indicate 
future research directions that should be pursued, as it has not been thoroughly investigated. 
The relationship between migraines and AD also may be due to a genetic 
relationship. Individuals with familial AD due to presenilin-1 mutations are more likely to 
suffer from migraines or recurrent headaches (Lopera et al., 1997; Ringman et al., 2008). 





Bugami & Loy-English, 2007; see reviews by Blennow, de Leon & Zetterberg, 2006; 
Breslau & Rasmussen, 2001; Burns & Iliffe, 2009; Patterson et al., 2007). This possible 
genetic relationship may explain the association between migraines and AD. The results of 
stratification by family history of dementia might support a possible genetic relationship 
between migraines and AD that warrants future research using APOE data. Those suffering 
from migraines with a family history of dementia were more likely to develop AD, compared 
to those without a family history of dementia. Despite this result not being statistically 
significant, it is interesting as we used family history of dementia as a proxy for APOE, since 
the MSHA does not have genetic information for participants. This possible genetic 
relationship has not been fully investigated and may be a fruitful avenue future research. 
 In addition to stratifying by family history of dementia, stratification by sex was 
attempted. However, this thesis project was unable to stratify by sex because no male 
participants suffered from migraines as well as dementia, and only one male participant 
suffered from migraines as well as CIND. This is an intriguing descriptive result, as of the 
participants with migraines, only female participants developed dementia. The literature has 
demonstrated that women are more likely to suffer from migraines (see reviews by Bigal & 
Lipton, 2009; Lipton & Bigal, 2005 a, b) and are at an increased risk of developing AD 
(Alzheimer’s Association, 2009; see review by Musicco, 2010). This unanswered question 
regarding the possible increased risk for women should be addressed in future research.  
A protective relationship was observed between migraines and CIND; however this 
relationship was not statistically significant. CIND is often considered an early stage of AD 
and those who suffered from migraines were more likely to develop AD. It has been 





criteria for AD (see review by Tedeschi et al., 2008). If those suffering from CIND were 
mostly young older adults (i.e. 65-70 years of age), this might indicate that the participants 
still had time to progress to AD as they aged. However, the mean age of those with CIND 
was 80.3 years, ranging from 69 years old to 98 years old. This suggests that many of those 
suffering from CIND in this sample will not progress to AD, as these participants are already 
among some of the oldest old. A closer look at individuals with CIND in this sample informs 
us that the majority of participants with CIND have a specific sub-type of CIND or a specific 
cause of CIND that is not likely to progress to AD. For example, seven participants were 
diagnosed with CIND due to depression; six participants with CIND were diagnosed with an 
age-associated sub-type of CIND. These descriptive results suggest that the non-significant 
protective relationship observed between migraines and CIND may only be generalizable to 
those suffering from sub-types of CIND that will not progress to AD. Depression was a 
significant risk factor for CIND, and the strength of association between migraines and 
CIND did not change with the inclusion of depression. This is most likely due to the seven 
participants diagnosed with CIND caused by depression. Alternatively, this relationship may 
also be related to the occurrence of depressive symptoms early in those who develop 
dementia or some type of cognitive impairment (Gatz et al., 2005 b; Luchsinger et al., 2008; 
Ownby et al., 2006; see review by Patterson et al., 2007). In addition, depression has been 
shown to be a risk factor for and comorbid with migraines, which may also explain the above 
relationship (Breslau et al., 2003; Patel et al. 2004). Further research is required to clarify the 







It is important for the results of this study to be interpreted in the context of its 
various limitations. There are a variety of limitations that should be noted with regard to the 
available data and various analytic methods that have been used. The following sections 
address several key limitations that should be taken into account when interpreting the results 
of this study. 
 
7.2.1. Sample  
The study used data from individuals who completed the MSHA-Risk Factor 
Questionnaire, were cognitively intact at MSHA-1 (n=1039) and had all relevant information 
available at MSHA-2 (n=716). After a detailed examination of study sample characteristics, 
participants who were included in the final analytic sample (n=716) were found to be 
younger and healthier than those who were excluded due to missing values on key variables. 
Thus, the results of this study are most appropriately generalized to a younger and healthier 
older adult population. This introduces a potential selection bias in this study and may affect 
the generalizability of the results. However, this potential bias is unavoidable, due to the 
sample restrictions that were made. Younger and healthier older adults were more likely to 
be able to complete the various interviews involved in the MSHA study leading to a largely 
younger, healthier sample. Additionally, as the sample was restricted to those without 
missing data, participants who did not answer certain questions may have different traits and 
characteristics than those who did answer. These participants’ characteristics were not able to 






7.2.2. MSHA Data  
The analyses of this project were based on secondary data that had been previously 
collected by the MSHA. Analyses conducted using secondary data may have some 
limitations such as reliance on the quality of previously collected data, which was not 
collected with the intended use of the specific research questions of this study. 
Migraine data were self-reported and did not include medical records with migraine 
diagnoses based on standardized migraine criteria (i.e., IHS: ICHD-II). Fortunately, self-
reported migraine has been shown to have excellent agreement with the IHS: ICHD-II 
criteria for migraine diagnoses (Schurks, Buring & Kurth, 2009). In addition, the MSHA 
questions on migraines did not distinguish between migraines with and without aura. The 
type of migraine however, does not appear to be a vital characteristic of migraine exposure, 
since both types cause similar long-term neurological damage (see review by Hamed, 2009). 
The health questions regarding migraines do not include some characteristics of migraine 
disorders, such as use of migraine medications, number of migraine attacks in a month, and 
severity or intensity of migraine attacks. However, the survey questions pertaining to 
migraines include the most essential features, such as whether the survey participant 
experienced migraines, as well as limited data on duration of the migraine disorder.  
Another limitation of the MSHA data is the lack of clinical and genetic information. 
Thorough clinical information, such as blood pressure and cholesterol level, would help 
support many aspects of the study (i.e., intervening variables). Clinical diagnoses of CVD 
and related disorders may be more reliable than self-reports of these health issues. Clinical 





pathology tests would also provide useful medical information. Such in-depth clinical 
examinations, however, are not feasible for all participants of large epidemiologic studies. 
Genetic information, specifically APOE status, would also have been useful in 
determining participants at increased risk of developing dementia. “Family history of 
dementia: Alzheimer’s disease and senile dementia,” was used as a proxy for genetic risk of 
all types. Although the “family history of dementia” variable is not as specific as APOE, it 
could be a useful variable to help identify groups at risk from APOE and other genetic 
factors. However, the variable family history of dementia is not an ideal proxy for APOE 
status. This variable does not identify which participants have genes that increase the risk of 
developing dementia or AD, since many cases are due to environmental rather than genetic 
factors. In addition, APOE status does not necessarily determine whether an individual will 
develop dementia or AD. 
Although the MSHA utilized thorough clinical diagnostic criteria to identify 
cognitively impaired participants, the MSHA lacked neuropathological data. However, a 
neuropathologic diagnosis cannot be made without an autopsy and thus is rare for large 
population-based studies. Another possible limitation due to diagnostic criteria is the wide 
range of definitions and standards. Depending on the criteria used, risk factors as well as 
incidence and prevalence may vary in different studies. However, the diagnostic criteria used 
by the MSHA for assessment and diagnosis of cognitive impairment were standard at the 
time of data collection and remain well-accepted criteria. 
A common issue in older adult populations is polypharmacy, i.e. the use of too many 
medications or the prescription of multiple medications. Polypharmacy may influence the 





This issue may cause problems with unadjusted confounding. Many vascular risk factors for 
dementia, such as the intervening variables in this thesis, have common medications 
prescribed to help control the condition or disorder. Due to this unadjusted confounding, any 
effect that the intervening variables may have on the relationship between migraines and 
dementia may not be seen. For instance, if a participant is taking antihypertensive 
medication, the effect of hypertension on the relationship between migraines and dementia 
may not be seen. Unfortunately, the MSHA only has data on medication use for a subset of 
the sample and thus it was not possible to adjust for medications. 
 
7.2.3. Data Analyses 
 The relatively small sample sizes in certain analyses contributed to the inability to 
develop final models for migraine duration and to stratify models by sex and family history 
of dementia. There is the potential for confounding in the duration of migraine disorder 
models, as the sample size was insufficient to adjust for potential confounding variables. 
There is also the potential for confounding in the unadjusted dementia model stratified by 
family history of dementia. Since no male participants suffered from migraines as well as 
dementia and only one male participant suffered from migraines as well as CIND, 
stratification of each model by sex was not possible. 
 
7.2.4. General Issues 
Various challenges are inherent to late-life cognitive impairment research. Such 
challenges include the timing between risk factors and disease development and the variety 





occur during early or mid-life, such as occupational exposures or low educational level. For 
example, the peak prevalence of migraines occurs during mid-life, whereas the peak 
prevalence of dementia is in late-life. The gap between peak prevalence of several decades in 
these neurological disorders may make it difficult to establish a direct causal connection.  
Another challenge when studying cognitive impairment is the wide variety of 
definitions used to diagnose and categorize the many types of cognitive impairments. The 
field of research will often determine the accepted definition to use, either based on clinical 
or pathologic criteria. The MSHA used a clinical definition to diagnose cognitive impairment 
in its participants. Therefore, the results from this thesis are most readily generalizable to 
populations diagnosed clinically and other studies using clinical diagnostic criteria. 
 
7.3. Strengths 
Despite the various limitations discussed, there are many important strengths related 
to the thesis project. The MSHA is a large, population-based, longitudinal survey examining 
aging and dementia. A longitudinal study design with two screening time points allows for 
the investigation of predictors of incident cases of the cognitive outcomes, rather than 
prevalent cases. This is important as incidence measures the risk of developing a cognitive 
outcome, compared to prevalence, which measures the total number of people with a 
cognitive outcome in a population. Another important strength of the MSHA is that the study 
population includes both rural and urban populations. Analyzing data from a population-
based study with such a large, diverse sample size, such as the MSHA, allows for greater 





The MSHA has a standardized diagnostic protocol to determine the final cognitive 
outcome of the survey participants. This allows confidence in the assessment of various 
cognitive outcomes (overall dementia, AD, VaD, and CIND) as our end points. Furthermore, 
the MSHA data set questionnaire included a wide range of questions on health history, which 
allowed this thesis project to examine multiple confounding and intervening variables. These 
strengths allowed a comprehensive examination of the relationship between migraines and 
late-life cognitive health outcomes. 
 
7.4. Implications and Future Research Directions 
Further research is required to understand the possible relationships between 
migraines and late-life cognition. Identifying risk factors for cognitive health outcomes in 
late-life is an important research area, given the current and expected increases in the 
proportion of older adults in the population.  
The possible relationship between cognitive domains affected by migraine long-term 
neurological damage and subsequent development of a late-life cognitive outcomes should 
be investigated further. Cognitive domains affected by migraines may indicate the type of 
cognitive impairment that an individual is at risk of developing in late life. This area has yet 
to be investigated. 
This research project has attempted to provide further insight into various effect 
modifiers on cognitive health outcomes. However, this project was unable to address the 
effect that sex has on the relationship between migraines and late-life cognitive health 
outcomes. Future studies utilizing a larger sample of those with a history of migraines, both 





project was only able to stratify by family history of dementia in an unadjusted dementia 
model. Despite the lack of significant results, further studies using APOE and genes 
identified in certain types of migraines may help us to better understand the relationship 
between migraines and AD. The possible genetic relationship between migraines and AD 
should be investigated further, as some studies have observed that those with AD gene 
mutations are more likely to suffer from migraines or recurrent headaches. Furthermore, 
research on both migraines and AD has implicated chromosomes 1 and 19. This possible 
genetic relationship between these two disorders has not been fully investigated. 
It is critical to identify at-risk groups as early as possible in order to attempt to 
prevent cognitive decline and improve overall health. Identifying a mid-life risk factor for 
cognitive outcomes in late life will allow earlier recognition of at-risk individuals and allow 
for migraine or vascular-related interventions. Additionally, migraines may represent a 
modifiable risk factor for AD, as interventions such as migraine medications or reduction of 
vascular risk factors may decrease the risk of developing AD. Future studies should explore 
the relationship between various migraine medications and possible reductions in the risk of 
late-life cognitive health outcomes. Vascular risk factors, such as hypertension, 
hypercholesterolemia and diabetes, should also be examined in relation to migraine 
medication and late-life cognitive health outcomes, as many migraine medications target 
vascular issues. Addressing both migraine and any related vascular risk factors would allow 
for more targeted treatment and subsequent reduced risk of late-life cognitive health 
outcomes. 
The relationship between migraines, stroke, and VaD should be investigated further. 





for VaD, there may be some unidentified aspect of this relationship that was unable to be 
addressed by this thesis project. Furthermore, the relationship between migraines and CIND 
raised more questions than it answered regarding a potential protective relationship, as well 
as the role depression may play. Future studies involving a larger population of those 
diagnosed with CIND, with a variety of subtypes, could answer some of these questions and 
clarify the association between migraines and CIND. 
Migraines cause a cascade of pathophysiologic events in the brain. In order to 
understand more fully how migraines affect cognitive health, studies involving animal 
models can be performed to determine the possible biological mechanisms that may link 
migraines and late-life cognitive health outcomes. This would allow more targeted 
pharmaceutical interventions and treatments to be manufactured and tested. 
The association between migraines and late-life cognitive health outcomes may vary 
by subgroups. This area of research has yet to be fully investigated. This project has 
identified that stroke may play an important part in the migraine-VaD relationship. A 
potential association with depression, migraines and CIND has also been observed. Those 
with a history of migraines as well as stroke or depression may represent subgroups at 
increased risk of developing late-life cognitive health outcomes. It is possible that there may 
be other subgroups of high-risk individuals that have yet to be identified.  
Identifying the association of migraines with late-life cognitive health outcomes and 
the role of intervening variables in this association has important implications for researchers 
and clinicians in the form of non-pharmaceutical interventions, preventative treatments and 
medications. It is critical to continue to develop new strategies that will help prevent 
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Appendix A: Epidemiologic Studies Assessing Cognitive Impairment or Cognitive Performance in Migraine Sufferers 
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Appendix B: Coding of Education: Removal of “Other” Category from the Educational 
Level Variable 
 
Seventeen participants from the study sample (n=1039) were included in the “other” 
category of the educational level variable. This category had no additional description. To 
further understand the “other” category, bivariate analyses were performed between 
educational level and years of education. Participants in the “other” category achieved 
between 9 and 22 years of education. Since the range of years of education attained in the 
“other” category was so wide, we were unable to include those individuals in one of the 
alternate educational level categories. 
Assessment of education level by migraine and cognitive outcomes, indicated that 
only one participant from the “other” category reported a history of migraines and none of 
the participants in the “other” category were diagnosed with a late-life cognitive health 
outcome. 
Comparing the selection bias results when including the “other” category to the 
results excluding the “other” category demonstrated that the samples did not differ 
significantly. When comparing potential selection bias of the n=978 vs. n=1039 to the n=961 
vs. n=1039, the prevalence of VaD did not differ significantly, converting from marginally 
significant (p-value=0.053) to non-significant (p-value=0.18). The prevalence of CIND also 
did not change significantly, shifting from marginally significant (p-value=0.094) to non-
significant (p-value=0.42). Other heart condition prevalence went from non-significant (p-





When comparing the potential selection bias of the n=727 vs. n=978 to the n=716 vs. 
n=716, the prevalence of VaD converted from significant (p-value: 0.044) to marginally 







Appendix C: MSHA and MSHA-2 Variables for the Study 
 
Variable Description MSHA Dataset: Variable Source     
  MSHA-1 (scr.) MSHA-1 (risk factor) MSHA-2 (scr.) v.1, v.2 Role 
Date of Screening Interview T1_Day, T1_Month, T1_year   T2_Day, T2_Month, T2_Year Descriptor 
T1 Status Variables CONDIAG     Descriptor 
T2 Screening Status     SCRSTAT2 Descriptor 
MSHA-2 Screening Interview Version     SCRVER, VERSION Descriptor 
Provincial Subject Identification PROVID   PROVID Descriptor 
Sex SEX     
Confounding Variable/ 
Effect Modifier 
Years of Education Completed EDUYEAR     Confounding Variable 
Level of Education EDULEVEL     Confounding Variable 
Age at Screening Interview AGET1     Confounding Variable 
Depression   DEPRESSN, DEPYR   Confounding Variable 
Epilepsy   EPILEPSY, EPIYR   
Confounding Variable/ 
Effect Modifier 
Migraine   MIGRAINE, MIGYR   Exposure 
Alzheimer's disease (Family History)   ALZ1, ALZ2, ALZ3   
Effect Modifier- proxy for  
genetic risk 
Senile Dementia (Family History)   SEN1, SEN2, SEN3   
Effect Modifier- proxy for  
genetic risk 
Heart Attack   ATTACK, ATYR   Intervening Variable 
Other Heart condition   OHEART, HEYR   Intervening Variable 
Stroke   PRSTROKE, STRYR   Intervening Variable 
High Blood Pressure   PROXHBP, HBPYR   Intervening Variable 
Diabetes   PROXDIAB, DIAYR   Intervening Variable 
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 ( (SD)) 
.9 (20.1) 
.3 (21.0) 
.3 (20.7) 
.8 (21.2) 
.3 (18.8) 
.0 (20.6) 
.6 (20.1) 
Female 
.8 (21.2) 
rrelation 
efficient 
 
.14 
.16 
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p-valu
0.9 
0.65
0.37
0.08
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